Page last updated: 2024-11-04

mefloquine hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mefloquine hydrochloride is an antimalarial drug that is used to prevent and treat malaria. It is effective against the parasite Plasmodium falciparum, which is responsible for the most severe form of malaria. Mefloquine hydrochloride is a synthetic drug that was first developed in the 1970s. It is thought to work by interfering with the parasite's ability to reproduce. Mefloquine hydrochloride is taken orally, usually once a week for malaria prevention, or once a day for treatment. It can cause side effects such as dizziness, nausea, and headache. Mefloquine hydrochloride is a safe and effective drug for most people. However, it is not recommended for people with certain medical conditions, such as epilepsy or depression. Mefloquine hydrochloride is an important drug for the treatment and prevention of malaria, which is a serious public health problem in many parts of the world. It is studied to understand its effectiveness, safety, and potential for new drug development. It is also being studied for its potential to treat other conditions, such as cancer.'

[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65329
CHEMBL ID1606
CHEBI ID6719
SCHEMBL ID41094
MeSH IDM0024163
PubMed CID4046
CHEMBL ID416956
CHEBI ID63681
SCHEMBL ID21782
MeSH IDM0024163
PubMed CID441362
CHEMBL ID535650
SCHEMBL ID41095
MeSH IDM0024163

Synonyms (194)

Synonym
AC-4686
(as)?-?rel-?a-?(2r)?-?2-?piperidinyl-?2,8-?bis(trifluoromethyl)?-?4-?quinolinemethanol monohydrochloride
(r*,s*)-(1)-alpha-2-piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol monohydrochloride
4-quinolinemethanol, alpha-(2r)-2-piperidinyl-2,8-bis(trifluoromethyl)-, monohydrochloride, (alphas)-rel-
dl-erythro-alpha-2-piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol monohydrochloride
nsc 157387
ro-21-5998/001
4-quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, monohydrochloride, (r*,s*)-(+-)-
mefloquine hcl
mephaquin
einecs 257-412-0
mefloquine hydrochloride [usan]
wr 142490 hydrochloride
mefloquine hydrochloride, >=98% (hplc), powder
51742-86-0
MLS001332560
nsc-157387
ro 21-5998/001
lariam (tn)
D00831
mefloquine hydrochloride (jp17/usp)
ro-215998001
loriam
CHEMBL1606
dtxcid301473958
tox21_111999
cas-51773-92-3
dtxsid1047819 ,
M2313
AKOS015919767
S4420
5y9l3636o3 ,
mefloquine hydrochloride [usan:usp]
unii-5y9l3636o3
CS-1430
mefloquine (hydrochloride)
mefloquin hydrochloride
mefloquine hydrochloride [who-ip]
mefloquine hydrochloride [ep impurity]
dl-erythro-.alpha.-2-piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol monohydrochloride
mefloquine hydrochloride [mart.]
mefloquine hydrochloride [usp monograph]
mefloquini hydrochloridum [who-ip latin]
4-quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-, monohydrochloride, (r*,s*)- (+/-)-
326vc85gv6 ,
mefloquine hydrochloride [who-dd]
mefloquine hydrochloride [jan]
mefloquine hydrochloride, (+)
mefloquine hydrochloride [vandf]
mefloquine hydrochloride [orange book]
mefloquine hydrochloride [usp-rs]
unii-326vc85gv6
mefloquine hydrochloride [ep monograph]
HY-17437A
NC00622
(+/-)-mefloquine hcl
SCHEMBL41094
NCGC00161831-04
tox21_111999_1
4-quinolinemethanol, .alpha.-(2r)-2-piperidinyl-2,8-bis(trifluoromethyl)-, monohydrochloride, (.alpha.s)-
4-quinolinemethanol, .alpha.-(2r)-2-piperidinyl-2,8-bis(trifluoromethyl)-, hydrochloride (1:1), (.alpha.s)-
(s)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2r)-piperidin-2-yl]methanol;hydrochloride
Q-201345
(s)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2r)-piperidin-2-yl]methanol hydrochloride
GS-3621
(2,8-bis-trifluoromethylquinolin-4-yl)-piperidin-2-yl-methanol hydrochloride(r*,s*)
mefloquine hydrochloride, united states pharmacopeia (usp) reference standard
mefloquine hydrochloride, pharmaceutical secondary standard; certified reference material
mefloquine hydrochloride, european pharmacopoeia (ep) reference standard
CHEBI:6719
SW220098-1
rel-(s)-(2,8-bis(trifluoromethyl)quinolin-4-yl)((r)-piperidin-2-yl)methanol hydrochloride
(?s)-rel-?-(2r)-2-piperidinyl-2,3-bis(trifluoromethyl-4-quinolinemethanol hydrochloride
4-quinolinemethanol, a-(2r)-2-piperidinyl-2,8-bis(trifluoromethyl)-,monohydrochloride, (as)-rel-
CCG-268825
(r)-[2,8-bis(trifluoromethyl)quinolin-4-yl](2s)-piperidin-2-ylmethanol hydrochloride
HB9555
c17h16f6n2o . hcl
weswymrnzndgbx-ylcxcwdssa-n
4-quinolinemethanol, .alpha,-[(2r)-2-piperidinyl]-2,8-bis(trifluoromethyl)-, (.alpha.s)-, hydrochloride (1:1)
mefloquine hydrochloride (usp monograph)
mefloquine hydrochloride (ep monograph)
mefloquine hydrochloride (usan:usp)
4-quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, monohydrochloride, (r*,s*)-(+/-)-
mefloquine hydrochloride (usp-rs)
mefloquine hydrochloride (mart.)
mefloquine hydrochloride (ep impurity)
racemic mefloquine
ro-21-5998-001
BRD-A89585551-003-03-4
DIVK1C_000790
KBIO1_000790
lariam
SPECTRUM_001312
SPECTRUM5_001122
wr-142490
PRESTWICK2_000126
IDI1_000790
BPBIO1_000190
PRESTWICK3_000126
BSPBIO_000172
AB00052310
[(r*,s*)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol
alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol
DB00358
wr 142,490
NCGC00094994-01
NCGC00094994-02
KBIO2_004360
KBIO2_006928
KBIOGR_001392
KBIOSS_001792
KBIO3_002046
KBIO2_001792
SPBIO_002111
PRESTWICK1_000126
SPBIO_001591
SPECTRUM4_001066
PRESTWICK0_000126
SPECTRUM3_000953
SPECTRUM2_001516
NINDS_000790
SPECTRUM1503070
NCGC00094994-03
NCGC00094994-04
mefaquin
CHEMBL416956 ,
nsc-758233
chebi:63681 ,
gnf-pf-5544 ,
HMS502H12
HMS1922C09
[2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol
bdbm50022889
(s)-(2,8-bis-trifluoromethyl-quinolin-4-yl)-piperidin-2-yl-methanol
2,8-di(trifluoromethyl)-4-quinolyl-hexahydro-2-pyridinylmethanol(mefloquine)
rac-mefloquine
(2,8-bis-trifluoromethyl-quinolin-4-yl)-piperidin-2-yl-methanol( mefloquine)
(2,8-bis-trifluoromethyl-quinolin-4-yl)-piperidin-2-yl-methanol
2-[(2,8-bis-trifluoromethyl-quinolin-4-yl)-hydroxy-methyl]-piperidinium
melfoquine
[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol
(2,8-bis(trifluoromethyl)quinolin-4-yl)(piperidin-2-yl)methanol
(2,8-bis-trifluoromethyl-quinolin-4-yl)-piperidin-2-yl-methanol; (mefloquine or mf)
rel-(2,8-bis(trifluoromethyl)quinolin-4-yl)(piperidin-2-yl)methanol
(s)-(2,8-bis-trifluoromethyl-quinolin-4-yl)-(r)-piperidin-2-yl-methanol
(2,8-bis-trifluoromethyl-quinolin-4-yl)-(1-methyl-piperidin-2-yl)-methanol
alpha-2-piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol
4-quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-
einecs 256-468-3
mefloquinone
CCG-39182
FT-0628185
NCGC00094994-06
[2,8-bis(trifluoromethyl)quinolin-4-yl](piperidin-2-yl)methanol
49752-90-1
gtpl4252
(dl-erythro-.alpha.-2-piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol
SCHEMBL21782
4-quinolinemethanol, .alpha.-2-piperidinyl-2,8-bis(trifluoromethyl)-, (r*,s*)-(.+/-.)-
AB00052310_09
sr-05000001820
SBI-0051761.P002
AKOS030575625
BCP09262
Q736270
BRD-A89585551-003-08-3
SR-05000001820-11
EN300-1696285
STL581681
DTXSID50860636
threo-mefloquinehydrochloride
MLS002154206
smr001233492
PRESTWICK_538
TCMDC-124288 ,
CHEMBL535650
ro-21-5998
mefloquini hydrochloridum
HMS1568I14
nsc758233
pharmakon1600-01503070
FT-0640025
AB07167
CCG-213099
AB45053
(2,8-bis-trifluoromethyl-quinolin-4-yl)-piperidin-2-yl-methanol hydrochloride(r*,r*)
SCHEMBL41095
mefloquinehydrochloride
SR-05000001820-4
BCP01049
EN300-1696284
33433-59-9
[2,8-bis(trifluoromethyl)quinolin-4-yl](piperidin-2-yl)methanol hydrochloride

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Treatment-related adverse events for the two groups were similar (tafenoquine, 13."( Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
Brennan, L; Edstein, MD; Harris, IE; Kerr, C; Kitchener, SJ; Leggat, PA; Nasveld, PE; Ohrt, C; Pickford, P; Prescott, W; Reid, M, 2010
)
0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
" Competitive uptake of radiolabeled chloroquine and dihydroartemisinin in combination with other antimalarials was observed."( Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
Adagu, IS; Fivelman, QL; Warhurst, DC, 2007
)
0.34

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model."( Spiroindolones, a potent compound class for the treatment of malaria.
Beck, HP; Brun, R; Cohen, SB; Dartois, V; Dharia, NV; Diagana, TT; Fidock, DA; Goh, A; González-Páez, GE; Jegla, T; Keller, TH; Lakshminarayana, SB; Lee, MC; McNamara, C; Nosten, F; Plouffe, DM; Renia, L; Rottmann, M; Russell, B; Schmitt, EK; Seitz, P; Spencer, KR; Suwanarusk, R; Tan, J; Winzeler, EA; Yeung, BK; Zou, B, 2010
)
0.36
" The implementation of this assay to the screening of a highly diverse academic chemical library of 14,300 molecules yielded, after secondary assays and generation of dose-response curves, the identification of two natural product inhibitors, cyanidin and delphinidin."( Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme.
Haiech, J; Hibert, M; Kellenberger, E; Kuhn, I; Lobstein, A; Muller-Steffner, H; Rognan, D; Said-Hassane, F; Schuber, F; Villa, P, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (5)

ClassDescription
hydrochlorideA salt formally resulting from the reaction of hydrochloric acid with an organic base.
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
piperidines
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (97)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency1.58490.044717.8581100.0000AID485294
glp-1 receptor, partialHomo sapiens (human)Potency11.22020.01846.806014.1254AID624417
RAR-related orphan receptor gammaMus musculus (house mouse)Potency29.84930.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency9.52050.173734.304761.8120AID1346924
ATAD5 protein, partialHomo sapiens (human)Potency25.91850.004110.890331.5287AID504466
Fumarate hydrataseHomo sapiens (human)Potency35.48130.00308.794948.0869AID1347053
SMAD family member 3Homo sapiens (human)Potency9.52050.173734.304761.8120AID1346924
TDP1 proteinHomo sapiens (human)Potency8.71700.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency19.77830.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency28.91500.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency26.60320.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency13.33320.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency30.23100.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency28.60080.000417.946075.1148AID1346784; AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency8.15740.01237.983543.2770AID1346984; AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency26.83250.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency27.06780.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency9.00290.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency33.49150.001530.607315,848.9004AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency33.48890.375827.485161.6524AID743217
estrogen nuclear receptor alphaHomo sapiens (human)Potency19.98760.000229.305416,493.5996AID743069; AID743075; AID743078; AID743079
GVesicular stomatitis virusPotency43.64860.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency8.70900.00108.379861.1304AID1645840
polyproteinZika virusPotency35.48130.00308.794948.0869AID1347053
67.9K proteinVaccinia virusPotency25.11890.00018.4406100.0000AID720580
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency10.41470.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency16.03050.001019.414170.9645AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency20.41570.023723.228263.5986AID743222; AID743223; AID743241
caspase-3Homo sapiens (human)Potency26.60320.013326.981070.7614AID1346978
IDH1Homo sapiens (human)Potency9.20000.005210.865235.4813AID686970
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency23.71010.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency21.20130.001628.015177.1139AID1224895; AID1259385
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency9.52210.154917.870243.6557AID1346891
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency18.995919.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency5.89390.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency55.19650.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency33.49150.006723.496068.5896AID1346980
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency112.20203.548119.542744.6684AID743266
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency10.00000.01789.637444.6684AID588834
caspase-3Cricetulus griseus (Chinese hamster)Potency33.49150.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency6.07220.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency23.41050.000627.21521,122.0200AID743202; AID743219
gemininHomo sapiens (human)Potency14.64940.004611.374133.4983AID624296; AID624297
Interferon betaHomo sapiens (human)Potency38.47130.00339.158239.8107AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency43.64860.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency28.22630.002319.595674.0614AID651631; AID720552
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency43.64860.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency28.81020.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency26.60320.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency43.64860.01238.964839.8107AID1645842
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
Fumarate hydrataseHomo sapiens (human)Potency10.49040.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency23.36170.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency7.75360.000811.382244.6684AID686978; AID686979
EWS/FLI fusion proteinHomo sapiens (human)Potency25.34650.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
polyproteinZika virusPotency10.49040.00308.794948.0869AID1347053
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency39.81070.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency25.11890.316212.765731.6228AID881
Interferon betaHomo sapiens (human)Potency23.36170.00339.158239.8107AID1347411
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency25.11890.00638.235039.8107AID881
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
glp-1 receptor, partialHomo sapiens (human)Potency11.22020.01846.806014.1254AID624417
ATAD5 protein, partialHomo sapiens (human)Potency32.28110.004110.890331.5287AID504466; AID504467
TDP1 proteinHomo sapiens (human)Potency16.36010.000811.382244.6684AID686978
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
67.9K proteinVaccinia virusPotency17.03900.00018.4406100.0000AID720579; AID720580
glucocerebrosidaseHomo sapiens (human)Potency17.78280.01268.156944.6684AID2101
IDH1Homo sapiens (human)Potency12.99530.005210.865235.4813AID686970
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency44.66843.548119.542744.6684AID743266
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency50.11870.794321.275750.1187AID624246
flap endonuclease 1Homo sapiens (human)Potency0.63100.133725.412989.1251AID588795
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency7.07950.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency7.07950.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency7.07950.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency14.62820.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ubiquitin-conjugating enzyme E2 NHomo sapiens (human)IC50 (µMol)20.00000.873010.721978.4000AID493155
Histidine-rich protein PFHRP-IIPlasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)315.00000.07651.12552.9000AID278900
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)4.33000.00022.45859.9600AID1804171
MO15-related protein kinase Pfmrk Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)12.00000.70004.32007.0000AID242065
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)4.83560.00091.901410.0000AID240820; AID243151; AID408340; AID576612
ubiquitin-conjugating enzyme E2 NHomo sapiens (human)IC50 (µMol)20.00000.873010.721978.4000AID493155
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)5.62340.00091.901410.0000AID161281
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinBetacoronavirus England 1EC50 (µMol)11.48000.00304.57559.8200AID1804127
Replicase polyprotein 1abBetacoronavirus England 1EC50 (µMol)11.48000.00304.57559.8200AID1804127
Transmembrane protease serine 2Homo sapiens (human)EC50 (µMol)11.48000.00304.51689.8200AID1804127
Procathepsin LHomo sapiens (human)EC50 (µMol)11.48000.00304.48749.8200AID1804127
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusEC50 (µMol)11.48000.00304.61369.8200AID1804127
Replicase polyprotein 1abHuman coronavirus 229EEC50 (µMol)11.48000.00304.61369.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusEC50 (µMol)11.48000.00304.45549.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2EC50 (µMol)11.48000.00304.11059.8200AID1804127
Glycine receptor subunit alpha-1Homo sapiens (human)EC50 (µMol)2.50000.32001.45774.2000AID1203550
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusEC50 (µMol)11.48000.00304.57559.8200AID1804127
Angiotensin-converting enzyme 2 Homo sapiens (human)EC50 (µMol)11.48000.00304.57559.8200AID1804127
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
interferon gamma precursorHomo sapiens (human)AC5013.45500.128015.173038.6100AID1259418; AID1259420
MSHDrosophila melanogaster (fruit fly)AC5046.85000.20909.578848.6900AID743444
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (293)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
viral translationTransmembrane protease serine 2Homo sapiens (human)
proteolysisTransmembrane protease serine 2Homo sapiens (human)
protein autoprocessingTransmembrane protease serine 2Homo sapiens (human)
positive regulation of viral entry into host cellTransmembrane protease serine 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
startle responseGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
startle responseGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processGlycine receptor subunit alpha-1Homo sapiens (human)
monoatomic ion transportGlycine receptor subunit alpha-1Homo sapiens (human)
chloride transportGlycine receptor subunit alpha-1Homo sapiens (human)
muscle contractionGlycine receptor subunit alpha-1Homo sapiens (human)
neuropeptide signaling pathwayGlycine receptor subunit alpha-1Homo sapiens (human)
acrosome reactionGlycine receptor subunit alpha-1Homo sapiens (human)
visual perceptionGlycine receptor subunit alpha-1Homo sapiens (human)
adult walking behaviorGlycine receptor subunit alpha-1Homo sapiens (human)
neuronal action potentialGlycine receptor subunit alpha-1Homo sapiens (human)
neuromuscular process controlling postureGlycine receptor subunit alpha-1Homo sapiens (human)
negative regulation of transmission of nerve impulseGlycine receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, glycinergicGlycine receptor subunit alpha-1Homo sapiens (human)
righting reflexGlycine receptor subunit alpha-1Homo sapiens (human)
excitatory postsynaptic potentialGlycine receptor subunit alpha-1Homo sapiens (human)
inhibitory postsynaptic potentialGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to amino acid stimulusGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to zinc ionGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to ethanolGlycine receptor subunit alpha-1Homo sapiens (human)
response to alcoholGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of presynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGlycine receptor subunit alpha-1Homo sapiens (human)
positive regulation of acrosome reactionGlycine receptor subunit alpha-1Homo sapiens (human)
chemical synaptic transmissionGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of signaling receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cytokine productionAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin-mediated drinking behaviorAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme 2 Homo sapiens (human)
tryptophan transportAngiotensin-converting enzyme 2 Homo sapiens (human)
viral life cycleAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of transmembrane transporter activityAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cell population proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of smooth muscle cell proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of inflammatory responseAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of amino acid transportAngiotensin-converting enzyme 2 Homo sapiens (human)
maternal process involved in female pregnancyAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of cardiac muscle contractionAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane fusionAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeAngiotensin-converting enzyme 2 Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme 2 Homo sapiens (human)
entry receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of gap junction assemblyAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cardiac conductionAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of L-proline import across plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (106)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
serine-type endopeptidase activityTransmembrane protease serine 2Homo sapiens (human)
protein bindingTransmembrane protease serine 2Homo sapiens (human)
serine-type peptidase activityTransmembrane protease serine 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
transmembrane signaling receptor activityGlycine receptor subunit alpha-1Homo sapiens (human)
protein bindingGlycine receptor subunit alpha-1Homo sapiens (human)
zinc ion bindingGlycine receptor subunit alpha-1Homo sapiens (human)
glycine bindingGlycine receptor subunit alpha-1Homo sapiens (human)
extracellularly glycine-gated chloride channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
taurine bindingGlycine receptor subunit alpha-1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
neurotransmitter receptor activityGlycine receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
virus receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
metallocarboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
identical protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (72)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular regionTransmembrane protease serine 2Homo sapiens (human)
nucleoplasmTransmembrane protease serine 2Homo sapiens (human)
plasma membraneTransmembrane protease serine 2Homo sapiens (human)
extracellular exosomeTransmembrane protease serine 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
external side of plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
membraneGlycine receptor subunit alpha-1Homo sapiens (human)
dendriteGlycine receptor subunit alpha-1Homo sapiens (human)
neuron projectionGlycine receptor subunit alpha-1Homo sapiens (human)
neuronal cell bodyGlycine receptor subunit alpha-1Homo sapiens (human)
perikaryonGlycine receptor subunit alpha-1Homo sapiens (human)
intracellular membrane-bounded organelleGlycine receptor subunit alpha-1Homo sapiens (human)
synapseGlycine receptor subunit alpha-1Homo sapiens (human)
postsynaptic membraneGlycine receptor subunit alpha-1Homo sapiens (human)
inhibitory synapseGlycine receptor subunit alpha-1Homo sapiens (human)
glycinergic synapseGlycine receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGlycine receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGlycine receptor subunit alpha-1Homo sapiens (human)
synapseGlycine receptor subunit alpha-1Homo sapiens (human)
neuron projectionGlycine receptor subunit alpha-1Homo sapiens (human)
plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
endoplasmic reticulum lumenAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
ciliumAngiotensin-converting enzyme 2 Homo sapiens (human)
cell surfaceAngiotensin-converting enzyme 2 Homo sapiens (human)
membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
apical plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
endocytic vesicle membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane raftAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (755)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347150Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347155Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID759717Antimalarial activity against multidrug-resistant Plasmodium falciparum TM90C2A after 72 hrs by MSF assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.
AID759720Inhibition of Clostridium botulinum recombinant BoNT/A light chain at 20 mM by reverse-phase HPLC analysis2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.
AID759719Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 after 72 hrs by MSF assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID759718Antimalarial activity against multi drug resistant Plasmodium falciparum TM91C235 after 72 hrs by MSF assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1674381Antimalarial activity against Plasmodium falcipuram K1 by microculture radioistope technique2020Journal of natural products, 07-24, Volume: 83, Issue:7
Highly Modified Lanostane Triterpenes from the Wood-Rot Basidiomycete
AID1651823Antiplasmodial activity against Plasmodium falciparum K1 assessed as reduction in [3H]-hypoxanthine after 42 hrs by microculture radioisotope technique2020Journal of natural products, 04-24, Volume: 83, Issue:4
Antimalarial 9-Methoxystrobilurins, Oudemansins, and Related Polyketides from Cultures of Basidiomycete
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID759721Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 after 72 hrs by MSF assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.
AID759716Antimalarial activity against multidrug-resistant Plasmodium falciparum TM90C2B after 72 hrs by MSF assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.
AID1899037Antimalarial activity against Plasmodium berghei ANKA infected in BALB/c mouse assessed as time required for clearance of blood parasites at 9 mg/kg, ip administered daily for 5 days2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID1899039Antimalarial activity against Plasmodium berghei ANKA infected in BALB/c mouse assessed as increase in animal survival rate at 9 mg/kg, ip administered daily for 5 days and measured for 30 days2022European journal of medicinal chemistry, Jan-15, Volume: 228Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID318612Antimalarial activity against Plasmodium falciparum D62008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Chemical stability of the peroxide bond enables diversified synthesis of potent tetraoxane antimalarials.
AID337541Selectivity index, ratio of ED50 for human KB cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID135327BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID636075Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 after 48 hrs by lactate dehydrogenase assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Synthesis, biological evaluation and mechanistic studies of totarol amino alcohol derivatives as potential antimalarial agents.
AID267109Antimalarial activity against Plasmodium falciparum TM91C2352006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Tetraoxane antimalarials and their reaction with Fe(II).
AID334842Antimalarial activity after 24 hrs against Plasmodium falciparum D6 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxic and antimalarial alkaloids from the bulbs of Crinum amabile.
AID585009Antimalarial activity against Plasmodium malariae trophozoite stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.
AID558837Antimalarial activity against Plasmodium falciparum IMT 31 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID617829Antimalarial activity against mefloquine-resistant and chloroquine-sensitive Plasmodium falciparum D62011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID575961Antimicrobial activity against Plasmodium falciparum subclone 3A26 containing 3 copy number of pfmdr1-containing amplicon on chromosome 5 assessed as growth inhibition by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID322131In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID377944Cytotoxicity against human KB cells after 72 hrs by SRB assay1999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID586607Antimalarial activity against ring stage of Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID359666Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D61992Journal of natural products, Dec, Volume: 55, Issue:12
Antimalarial activity of sesquiterpenes from the marine sponge Acanthella klethra.
AID357906Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D62001Journal of natural products, Sep, Volume: 64, Issue:9
Synthesis of new artemisinin analogues from artemisinic acid modified at C-3 and C-13 and their antimalarial activity.
AID158848Inhibitory activity against Plasmodium falciparum W22002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID519198Antimicrobial activity against Plasmodium vivax at the ring stage measured within 30 hrs by microscopy2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID334267Antimalarial activity against multidrug-resistant Plasmodium falciparum TM91C235 after 24 hrs by [3H]hypoxanthine uptake2002Journal of natural products, Apr, Volume: 65, Issue:4
Efficacy of scopadulcic acid A against Plasmodium falciparum in vitro.
AID457433Cytotoxicity against african green monkey Vero cells after 72 hrs2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs.
AID502657Cytotoxicity against BALB/c mouse splenocyte by [3H]thymidine incorporation assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Structure-activity relationships of mononuclear metal-thiosemicarbazone complexes endowed with potent antiplasmodial and antiamoebic activities.
AID1203550Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents after 1 to 4 days by two-electrode voltage clamp assay2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID402124Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes by [3H]hypoxanthine uptake1997Journal of natural products, Jul, Volume: 60, Issue:7
In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta.
AID518549Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as cure rate at 100 mg/kg, perorally administered as single dose measured on day 3 postinfection2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID490360Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13
Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases.
AID575969Antimicrobial activity against Plasmodium falciparum subclone 3C20 containing 2 copy number of pfmdr1-containing amplicon on chromosome 5 assessed as growth inhibition by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID544091Antimalarial activity against drug-resistant Plasmodium falciparum W22008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
AID158845Inhibitory activity against Plasmodium falciparum K12002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID586923Resistant index, ratio of EC50 for tafenoquine-resistant promastigotes of Leishmania major R4 to EC50 for promastigotes of Leishmania major MHOM/JL/80/Friedlin2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major.
AID158844Inhibitory activity against Plasmodium falciparum D62002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID617824Antimalarial activity against Plasmodium berghei infected in mouse assessed as complete cure at 40 mg/kg, po administered as single dose measured on day 312011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID338767Antimalarial activity against Plasmodium falciparum D6 in human erythrocytes after 24 hrs by [3H]hypoxanthine uptake
AID765270AUC/MIC in Mycobacterium tuberculosis infected mouse2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID518541Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as survival rate at 100 mg/kg, perorally administered as single dose2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID575967Antimicrobial activity against Plasmodium falciparum subclone 3C18 containing 3 copy number of pfmdr1-containing amplicon on chromosome 5 assessed as growth inhibition by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID510937Antimalarial activity against Plasmodium falciparum Dd2 containing attB site inserted in parasite genome and using CAM promoter driven expressing ATP4 D1247Y mutant after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID343938Antimalarial activity against chloroquine-resistant, mefloquine-sensitive Plasmodium falciparum RCS2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Mixed tetraoxanes containing the acetone subunit as antimalarials.
AID152000In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 Sierra Leone2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Structure-activity relationships of the antimalarial agent artemisinin. 8. design, synthesis, and CoMFA studies toward the development of artemisinin-based drugs against leishmaniasis and malaria.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID509292Toxicity in patient with malaria assessed as incidence of abnormal dreams at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID378977Antimalarial activity after 48 hrs against Plasmodium falciparum W2 by [3H]hypoxanthine uptake2006Journal of natural products, Jan, Volume: 69, Issue:1
Lupeol long-chain fatty acid esters with antimalarial activity from Holarrhena floribunda.
AID558831Antimalarial activity against Plasmodium falciparum PA assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID337527Cytotoxicity against human A431 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID558835Antimalarial activity against Plasmodium falciparum IMT Guy assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1201063Antiplasmodial activity against chloroquine/mefloquine-resistant Plasmodium falciparum SKF582015European journal of medicinal chemistry, Apr-13, Volume: 94Synthesis of isocryptolepine analogues and their structure-activity relationship studies as antiplasmodial and antiproliferative agents.
AID575962Antimicrobial activity against Plasmodium falciparum subclone 3A12 containing 2 copy number of pfmdr1-containing amplicon on chromosome 5 assessed as growth inhibition by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID519192Antimicrobial activity against Plasmodium falciparum trophozoites by microscopy treated during ring stage2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID159761Inhibition of Plasmodium falciparum W22000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker.
AID509315Toxicity in patient with malaria assessed as incidence of headache at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID558056Antimicrobial activity against Plasmodium falciparum harboring NDFCDD genotype after 72 hrs by SYBR green I assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria.
AID617804Antimalarial activity against chloroquine-sensitive and mefloquine-resistant Plasmodium falciparum D6 by SYBR Green I-based fluorescence assay2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID509294Toxicity in patient with malaria assessed as incidence of insomnia at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID402143Antimalarial activity against Plasmodium falciparum W2 by [3H]hypoxanthine uptake relative to gedunin1997Journal of natural products, Apr, Volume: 60, Issue:4
Antimalarial activity of tropical Meliaceae extracts and gedunin derivatives.
AID575976Ratio of IC50 for Plasmodium falciparum subclone 3A1 containing 1 copy number of pfmdr1-containing amplicon on chromosome 5 to IC50 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID575730Antimicrobial activity against drug pre-treated Plasmodium falciparum clone W2AL80 containing 3 copy number of pfmdr1-containing amplicon on chromosome 5 assessed as growth inhibition by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID509074Toxicity in patient with malaria assessed as incidence of abdominal pain at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID509076Toxicity in patient with malaria assessed as incidence of diarrhea at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID438477Selectivity index, ratio of IC50 for Vero cells to IC50 for Mycobacterium tuberculosis H37Rv by Alamar blue susceptibility assay2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
From serendipity to rational antituberculosis drug discovery of mefloquine-isoxazole carboxylic acid esters.
AID607065Antimalarial activity against Plasmodium falciparum K12011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Antimalarial pyrido[1,2-a]benzimidazoles.
AID322968Antimicrobial activity against Mycobacterium avium complex 101 infected C57BL/6 beige mouse spleen assessed as bacterial load at 40 mg/kg once daily 6 days a week for 4 weeks2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium.
AID279386Growth inhibition of Plasmodium falciparum 3D7 ring stage in infected erythrocytes after 72 hrs in DAPI fluorimetry2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
High-throughput Plasmodium falciparum growth assay for malaria drug discovery.
AID576573Antimalarial activity against Plasmodium vivax at the ring stage infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID575731Antimicrobial activity against Plasmodium falciparum subclone 3A7 containing 4 copy number of pfmdr1-containing amplicon on chromosome 5 assessed as growth inhibition by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID354688Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 as [3H]hypoxanthine uptake1996Journal of natural products, Jun, Volume: 59, Issue:6
Costaricine, a new antiplasmodial bisbenzylisoquinoline alkaloid from Nectandra salicifolia trunk bark.
AID509316Toxicity in patient with malaria assessed as incidence of fungal dermatitis at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID575965Antimicrobial activity against Plasmodium falciparum subclone 3A3 containing 1 copy number of pfmdr1-containing amplicon on chromosome 5 assessed as growth inhibition by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID390619Antimalarial activity against multidrug-resistant Plasmodium falciparum TM91C2352008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
New chimeric antimalarials with 4-aminoquinoline moiety linked to a tetraoxane skeleton.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID159766In vitro inhibitory activity against chloroquine-resistant Plasmodium falciparum W2 Indochina2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Mixed steroidal 1,2,4,5-tetraoxanes: antimalarial and antimycobacterial activity.
AID558842Antimalarial activity against Plasmodium falciparum IMT 16332 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID617813Antimalarial activity against Plasmodium berghei infected in mouse assessed as host survival at 320 mg/kg, po administered as single dose2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID617825Antimalarial activity against Plasmodium berghei infected in mouse assessed as complete cure at 80 mg/kg, po administered as single dose measured on day 312011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID446157Antimycobacterial activity against Mycobacterium tuberculosis H37Rv2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.
AID585012Antimalarial activity against Plasmodium ovale ring stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.
AID575984Ratio of IC90 for Plasmodium falciparum subclone 3A8 containing 3 copy number of pfmdr1-containing amplicon on chromosome 5 to IC90 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID354807Antiplasmodial activity against Plasmodium falciparum D61996Journal of natural products, Jul, Volume: 59, Issue:7
Antimalarial activity: the search for marine-derived natural products with selective antimalarial activity.
AID617801Antimalarial activity against chloroquine-sensitive and mefloquine-resistant Plasmodium falciparum D6 assessed as inhibition of [3H]hypoxanthine incorporation by liquid scintillation spectrometry2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID490361Therapeutic index, IC50 for Plasmodium falciparum W2 to IC50 for mice (Mus musculus) RAW264.7 cells2010Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13
Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases.
AID323683Reduction of [3H]dihydroartemisinin uptake in chloroquine-resistant Plasmodium falciparum K1 infected erythrocytes after 90 min2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID529761Antimicrobial activity against Plasmodium vivax harboring amplified Pvmdr1 gene2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.
AID636373Antimalarial activity against blood stage of Plasmodium berghei NK65 infected in po dosed rat assessed as inhibition of parasite growth2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Febrifugine analogue compounds: synthesis and antimalarial evaluation.
AID549607Antimalarial activity against mefloquine-resistant, chloroquine-sensitive Plasmodium falciparum D6 assessed as inhibition of [3H]hypoxanthine uptake2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
In vitro efficacy of 7-benzylamino-1-isoquinolinamines against Plasmodium falciparum related to the efficacy of chalcones.
AID558826Antimalarial activity against Plasmodium falciparum 3D7 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID754534Inhibition of hemozoin formation in parasite digestive vacuole extract by microtiter plate-based high-throughput assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID519976Antimalarial activity against early trophozoite-stage Plasmodium falciparum 3D7 infected in erythrocyte assessed as reduction in parasite hemoglobin content at 5 times IC50 after 8 hrs in presence of 40 uM protease inhibitor E642008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Differential effects of quinoline antimalarials on endocytosis in Plasmodium falciparum.
AID337534Selectivity index, ratio of ED50 for human LUC1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337542Selectivity index, ratio of ED50 for human KB-V1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID322132In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID554566Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 assessed as [3H]hypoxanthine incorporation2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Synthesis and antimalarial activities of cyclen 4-aminoquinoline analogs.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID337670Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected human erythrocytes after 24 hrs by [3H]hypoxanthine uptake1994Journal of natural products, Oct, Volume: 57, Issue:10
Thalifaberidine, a cytotoxic aporphine-benzylisoquinoline alkaloid from Thalictrum faberi.
AID510935Antimalarial activity against Plasmodium falciparum Dd2 containing attB site inserted in parasite genome and using EF1-alpha promoter driven expressing ATP4 D1247Y mutant after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID159625In vitro inhibitory activity against chloroquine-sensitive Plasmodium falciparum African D62002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Mixed steroidal 1,2,4,5-tetraoxanes: antimalarial and antimycobacterial activity.
AID510929Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone3 bearing P-type ATPase4 D1247Y mutations after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID558845Antimalarial activity against Plasmodium falciparum IMT K4 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID617809Antimalarial activity against Plasmodium berghei infected in mouse assessed as host survival at 20 mg/kg, po administered as single dose2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID509320Toxicity in patient with malaria assessed as incidence of arthralgia at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID318614Antimalarial activity against multidrug-resistant Plasmodium falciparum TM91C2352008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Chemical stability of the peroxide bond enables diversified synthesis of potent tetraoxane antimalarials.
AID337518Antimalarial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum W2 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337523Cytotoxicity against human Col1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID322129In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID337545Selectivity index, ratio of ED50 for mice (Mus musculus) P388 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID765272Cmax/MIC in Mycobacterium tuberculosis infected mouse2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID334843Antimalarial activity after 24 hrs against Plasmodium falciparum W2 infected in type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxic and antimalarial alkaloids from the bulbs of Crinum amabile.
AID558841Antimalarial activity against Plasmodium falciparum IMT 10500 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID323680Reduction of [3H]chloroquine uptake in chloroquine-resistant Plasmodium falciparum RSA11 infected erythrocytes after 90 min2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID444928Antiplasmodial activity against Plasmodium berghei infected in NMRI mice (Mus musculus) assessed as mice (Mus musculus) survival days at 3 mg/kg, perorally daily once for 3 consecutive days measured after 4 days post-infection2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID157849Growth inhibition of chloroquine-resistant Plasmodium falciparum KI2001Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16
Synthesis, antimalarial activity and inhibition of haem detoxification of novel bisquinolines.
AID562271Antimalarial activity against Plasmodium falciparum isolates assessed as parasite growth inhibition after 72 hrs by ELISA based histidine-rich protein 2 in vitro drug susceptibility assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Antimalarial activity of tigecycline, a novel glycylcycline antibiotic.
AID576576Antimalarial activity against Plasmodium vivax infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID605732Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes assessed as decrease in parasitemia after 72 hrs2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Imidazolopiperazines: hit to lead optimization of new antimalarial agents.
AID378393Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D62006Journal of natural products, Aug, Volume: 69, Issue:8
Biological activities and 3D QSAR studies of a series of Delisea pulchra (cf. fimbriata) derived natural products.
AID765271fAUC/MIC in Mycobacterium tuberculosis infected mouse2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID633934Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by alamar blue assay2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Mefloquine-oxazolidine derivatives, derived from mefloquine and arenecarbaldehydes: In vitro activity including against the multidrug-resistant tuberculosis strain T113.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID509300Toxicity in patient with malaria assessed as incidence of increase in bilirubin at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID510934Antimalarial activity against Plasmodium falciparum Dd2 containing attB site inserted in parasite genome and using EF1-alpha promoter driven expressing wild type ATP4 after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID510927Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone1 bearing P-type ATPase4 I398F and P990R mutations after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID157850Growth inhibition of chloroquine-sensitive Plasmodium falciparum D102001Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16
Synthesis, antimalarial activity and inhibition of haem detoxification of novel bisquinolines.
AID322135Antimalarial activity against Plasmodium falciparum W2 as reduced [3H]hypoxanthine uptake after 72 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID343939Antimalarial activity against mefloquine, chloroquine and quinine-resistant Plasmodium falciparum TM91C2352008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Mixed tetraoxanes containing the acetone subunit as antimalarials.
AID255870In vitro antimalarial activity for Plasmodium falciparum TM91C2352005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Unambiguous synthesis and prophylactic antimalarial activities of imidazolidinedione derivatives.
AID558827Antimalarial activity against Plasmodium falciparum W2 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID337526Cytotoxicity against mouse P388 cells after 2 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID457909Antimalarial activity against Plasmodium berghei infected in ICR mice (Mus musculus) assessed as delay in mortality at 160 mg/kg, perorally for 3 days2010Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum.
AID316376Antimalarial activity against Plasmodium falciparum D6 in MSF assay2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Synthesis and heme-binding correlation with antimalarial activity of 3,6-bis-(omega-N,N-diethylaminoamyloxy)-4,5-difluoroxanthone.
AID509077Toxicity in patient with malaria assessed as incidence of gastroentertis at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID511099Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 30 mg/kg, perorally administered through 7% Tween80/3% Ethanol formulation 24 hrs post infection for 3 days measured 962010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID438475Antitubercular activity against Mycobacterium tuberculosis H37Rv by low oxygen recovery assay2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
From serendipity to rational antituberculosis drug discovery of mefloquine-isoxazole carboxylic acid esters.
AID575986Ratio of IC90 for Plasmodium falciparum subclone 3A12 containing 2 copy number of pfmdr1-containing amplicon on chromosome 5 to IC90 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID558830Antimalarial activity against Plasmodium falciparum FCR3 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1201061Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D72015European journal of medicinal chemistry, Apr-13, Volume: 94Synthesis of isocryptolepine analogues and their structure-activity relationship studies as antiplasmodial and antiproliferative agents.
AID765269fT>MIC in Mycobacterium tuberculosis infected mouse2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID449198Antimalarial activity against Plasmodium falciparum W2mef ring form by hoechst 33342-thiazole orange stain based flow cytometry assay2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Addressing the malaria drug resistance challenge using flow cytometry to discover new antimalarials.
AID274300Cytotoxicity against L6 cells2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Antiprotozoal activities of new bis-chlorophenyl derivatives of bicyclic octanes and aza-nonanes.
AID358507Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum PFB Brazil by [3H]hypoxanthine uptake2001Journal of natural products, Jan, Volume: 64, Issue:1
Strychnogucines A and B, two new antiplasmodial bisindole alkaloids from Strychnos icaja.
AID399303Antimalarial activity against chloroquine-resistant Plasmodium falciparum Smith by semiautomated micro dilution assay
AID438478Selectivity index, ratio of IC50 for Vero cells to IC50 for Mycobacterium tuberculosis H37Rv by low oxygen recovery assay2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
From serendipity to rational antituberculosis drug discovery of mefloquine-isoxazole carboxylic acid esters.
AID490356Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13
Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases.
AID361514Antimalarial activity against multidrug-resistant Plasmodium falciparum TM91C2352008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Novel 4-aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID732339Antimalarial activity against chloroquine-resistant Plasmodium falciparum W22013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Discovery and structure-activity relationships of pyrrolone antimalarials.
AID337519Cytotoxicity against human BCA1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID558839Antimalarial activity against Plasmodium falciparum IMT 9881 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID563687Antimalarial activity against Plasmodium falciparum assessed as parasite growth inhibition after 48 hrs by [3H]hypoxanthin incorporation assay2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility.
AID247058Effective dose against chloroquine-resistant, pyrimethamine-resistant, mefloquine-sensitive Plasmodium falciparum K12005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
AID575729Antimicrobial activity against compound-sensitive Plasmodium falciparum clone W2 assessed as growth inhibition by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID518557Toxicity in NMRI mice (Mus musculus) infected with Plasmodium berghei ANKA at 100 mg/kg, perorally administered as single dose measured up to 30 days postinfection2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID399302Antimalarial activity against chloroquine-sensitive Plasmodium falciparum CAMP by semiautomated micro dilution assay
AID300101Cytotoxicity against rat L6 cells after 72 hrs by microplate assay2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Bicyclo[2.2.2]octyl esters of dialkylamino acids as antiprotozoals.
AID404450Antimalarial activity against Plasmodium falciparum TM91C235 by hypoxanthine uptake2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID444927Antiplasmodial activity against Plasmodium berghei infected in NMRI mice (Mus musculus) assessed as reduction of parasitaemia level at 3 mg/kg, perorally daily once for 3 consecutive days measured after 4 days post-infection2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
AID519193Antimicrobial activity against Plasmodium vivax at the ring stage by microscopy2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID754525Inhibition of hemozoin formation in 1 M acetate buffer at pH 4.8 after 4.17 hrs by microtiter-based high-throughput assay in presence of 0.012 mg/mL Tween 202013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID359665Cytotoxicity against human KB cells1992Journal of natural products, Dec, Volume: 55, Issue:12
Antimalarial activity of sesquiterpenes from the marine sponge Acanthella klethra.
AID617814Antimalarial activity against Plasmodium berghei infected in mouse assessed as host survival at 5 mg/kg, po administered as single dose measured on day 312011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID323684Reduction of [3H]dihydroartemisinin uptake in chloroquine-sensitive Plasmodium falciparum 3D7 infected erythrocytes after 90 min2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID558057Antimicrobial activity against Plasmodium falciparum harboring NGFSDD genotype after 72 hrs by SYBR green I assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria.
AID575991Ratio of IC90 for Plasmodium falciparum subclone 3C18 containing 3 copy number of pfmdr1-containing amplicon on chromosome 5 to IC90 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID457431Antitubercular activity against Mycobacterium tuberculosis H37Rv after 72 hrs by microplate alamar blue assay2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs.
AID509314Toxicity in patient with malaria assessed as incidence of viral infection at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID158035Inhibitory concentration against Plasmodium falciparum D6 infected erythrocytes1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID586612Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of [3H]hypoxanthine incorporation2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID636378Therapeutic index, ratio of MTD for Sprague-Dawley rat to MCD for blood stage of Plasmodium berghei NK652012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Febrifugine analogue compounds: synthesis and antimalarial evaluation.
AID678039Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 by SYBR green I-based assay2012Journal of natural products, Jul-27, Volume: 75, Issue:7
Busseihydroquinones A-D from the roots of Pentas bussei.
AID278818Antimalarial activity against Plasmodium falciparum Dd22007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
AID623328Antimalarial activity against chloroquine-resistant and mefloquine-sensitive Plasmodium falciparum W2 infected in human O-positive erythrocytes assessed as inhibition of parasite growth by [3H]hypoxanthine incorporation assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antimalarial activity of physalins B, D, F, and G.
AID158846Inhibitory activity against Plasmodium falciparum NF542002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID360325Antiplasmodial activity after 24 hrs against chloroquine-resistant, mefloquine-sensitive Plasmodium falciparum W2 infected human erythrocytes by [G-3H]hypoxanthine uptake2001Journal of natural products, May, Volume: 64, Issue:5
In vitro antiplasmodial activity of extracts of Tristaniopsis species and identification of the active constituents: ellagic acid and 3,4,5-trimethoxyphenyl-(6'-O-galloyl)-O-beta-D-glucopyranoside.
AID255857In vitro antimalarial activity for Plasmodium falciparum D62005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Unambiguous synthesis and prophylactic antimalarial activities of imidazolidinedione derivatives.
AID558034Antiviral activity against JC polyomavirus Mad1 infected in human PHFG cells assessed as inhibition of viral replication after 3 days2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID318613Antimalarial activity against Plasmodium falciparum W22008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Chemical stability of the peroxide bond enables diversified synthesis of potent tetraoxane antimalarials.
AID510912Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 10 mg/kg, perorally administered as single dose as single dose 24 hrs post infection for 1 day measured 72 hrs post infection2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID558029Antiviral activity against JC polyomavirus M1/SVEdelta infected in human SVG-A cells assessed as inhibition of viral replication after 3 days2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID361515Antimalarial activity against chloroquine-resistant Plasmodium falciparum W22008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Novel 4-aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A.
AID337543Selectivity index, ratio of ED50 for human KB-V1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID519197Antimicrobial activity against Plasmodium vivax trophozoites measured within 30 hrs by microscopy2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID575963Antimicrobial activity against Plasmodium falciparum subclone 3A17 containing 2 copy number of pfmdr1-containing amplicon on chromosome 5 assessed as growth inhibition by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID159746In vitro sensitivity for Plasmodium falciparum FcB1R2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker.
AID378398Selectivity index, ratio of IC50 for human KB cells to IC50 for Plasmodium falciparum W22006Journal of natural products, Aug, Volume: 69, Issue:8
Biological activities and 3D QSAR studies of a series of Delisea pulchra (cf. fimbriata) derived natural products.
AID378397Selectivity index, ratio of IC50 for human KB cells to IC50 for Plasmodium falciparum D62006Journal of natural products, Aug, Volume: 69, Issue:8
Biological activities and 3D QSAR studies of a series of Delisea pulchra (cf. fimbriata) derived natural products.
AID159742Inhibition of Plasmodium falciparum FCR32000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker.
AID575968Antimicrobial activity against Plasmodium falciparum subclone 3C10 containing 2 copy number of pfmdr1-containing amplicon on chromosome 5 assessed as growth inhibition by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID519978Antimalarial activity against Plasmodium falciparum 3D7 infected in erythrocyte assessed as reduction in endocytic vesicle content after 8 hrs by immunofluorescence microscopy2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Differential effects of quinoline antimalarials on endocytosis in Plasmodium falciparum.
AID1194357Antimalarial activity against multidrug-resistant Plasmodium falciparum thailand TM91C235 assessed as [3H]-hypoxanthine incorporation by liquid scintillation counting analysis2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Investigation into novel thiophene- and furan-based 4-amino-7-chloroquinolines afforded antimalarials that cure mice.
AID372429Trypanocidal activity against Trypanosoma cruzi Tulahuen C4 trypomastigotes infected in mouse macrophage by reporter dye assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
2,N6-disubstituted adenosine analogs with antitrypanosomal and antimalarial activities.
AID264204Antimalarial activity against multidrug-resistant Plasmodium yoelii nigeriensis in mice (Mus musculus) at 100 mg/kg/day peroral dose after 4 days2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice.
AID1202799Inhibition of human ERG expressed in CHL cells assessed as tail current at 10 uM after 7 mins by patch clamp assay relative to control2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Antimalarial activity of 4-amidinoquinoline and 10-amidinobenzonaphthyridine derivatives.
AID617816Antimalarial activity against Plasmodium berghei infected in mouse assessed as host survival at 20 mg/kg, po administered as single dose measured on day 312011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID267107Antimalarial activity against Plasmodium falciparum D62006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Tetraoxane antimalarials and their reaction with Fe(II).
AID444929Antiplasmodial activity against Plasmodium berghei infected in NMRI mice (Mus musculus) assessed as curing of parasitaemia at 3 mg/kg, perorally daily once for 3 consecutive days measured after 30 days post-infection2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The structure-activity relationship of the antimalarial ozonide arterolane (OZ277).
AID449197Antimalarial activity against Plasmodium falciparum W2mef by hypoxanthine uptake assay2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Addressing the malaria drug resistance challenge using flow cytometry to discover new antimalarials.
AID575964Antimicrobial activity against Plasmodium falciparum subclone 3A1 containing 1 copy number of pfmdr1-containing amplicon on chromosome 5 assessed as growth inhibition by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID1201059Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K12015European journal of medicinal chemistry, Apr-13, Volume: 94Synthesis of isocryptolepine analogues and their structure-activity relationship studies as antiplasmodial and antiproliferative agents.
AID617803Antimalarial activity against chloroquine, mefloquine and pyrimethamine-resistant Plasmodium falciparum TM90C2A assessed as inhibition of [3H]hypoxanthine incorporation by liquid scintillation spectrometry2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID337550Selectivity index, ratio of ED50 for human ZR-75-1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID765268T>MIC in Mycobacterium tuberculosis infected mouse2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID298580Antimalarial activity against Plasmodium falciparum D62007Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
Deoxycholic acid-derived tetraoxane antimalarials and antiproliferatives(1).
AID337521Cytotoxicity against human LUC1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID490359Cytotoxicity against human Hs578 cells after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13
Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases.
AID617821Antimalarial activity against Plasmodium berghei infected in mouse assessed as complete cure at 5 mg/kg, po administered as single dose measured on day 312011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID337538Selectivity index, ratio of ED50 for human COL1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID322972Antimicrobial activity against clarithromycin resistant-Mycobacterium avium complex 101 infected C57BL/6 beige mouse spleen assessed as bacterial load at 40 mg/kg once daily 6 days a week for 4 weeks2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium.
AID537630Inhibition of Schistosoma mansoni recombinant NAD+ glycohydrolase expressed in Pichia pastoris at up to 100 uM by continuous fluorometric method2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme.
AID563688Antimalarial activity against Plasmodium falciparum assessed as resistant isolates2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility.
AID279313Inhibition of Plasmodium falciparum in HRP2 ELISA2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.
AID337551Selectivity index, ratio of ED50 for human ZR-75-1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID402126Antiplasmodial activity against Plasmodium falciparum K1 infected human erythrocytes by [3H]hypoxanthine uptake1997Journal of natural products, Jul, Volume: 60, Issue:7
In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID343942Relative activity against Plasmodium falciparum W2 as ratio of IC90 to IC502008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Mixed tetraoxanes containing the acetone subunit as antimalarials.
AID586606Antimalarial activity against trophozoites stage of Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID754531Inhibition of hemozoin formation in 0.5 M acetate buffer at pH 4.8 after 12 hrs by tube-based high-throughput assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID510940Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia dosed in ETPGS formulation 1 day post infection measured 72 hrs post infection2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID404451Antimalarial activity against Plasmodium falciparum TM90C2A by hypoxanthine uptake2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID605733Antimalarial activity against Plasmodium falciparum W2 infected in human erythrocytes assessed as decrease in parasitemia after 72 hrs2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Imidazolopiperazines: hit to lead optimization of new antimalarial agents.
AID279388Growth inhibition of Plasmodium falciparum Dd2 ring stage infected erythrocytes after 72 hrs by DAPI fluorimetry2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
High-throughput Plasmodium falciparum growth assay for malaria drug discovery.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID595241Resistance index, ratio of IC50 for Plasmodium falciparum W2 to IC50 for Plasmodium falciparum D62011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.
AID361517Selectivity index, ratio of IC50 for multidrug-resistant Plasmodium falciparum chloroquine-resistant W2 to IC50 for chloroquine and mefloquine-susceptible Plasmodium falciparum D62008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Novel 4-aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A.
AID322126In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID558037Cytotoxicity against human SVG-A cells2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID518550Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as cure rate at 3 times 30 mg/kg, perorally measured on day 3 postinfection2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID558829Antimalarial activity against Plasmodium falciparum FCM29 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID457435Selectivity index, ratio of IC50 for african green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv by low oxygen recovery assay2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs.
AID337524Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID494494Antituberculosis activity against Mycobacterium tuberculosis2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
New quinoline derivatives: synthesis and investigation of antibacterial and antituberculosis properties.
AID393144Antitubercular activity against Mycobacterium tuberculosis H37Rv after 5 days by microplate alamar blue assay2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Synthesis and in vitro antitubercular activity of a series of quinoline derivatives.
AID151999In vitro antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 Indochina2003Journal of medicinal chemistry, Sep-25, Volume: 46, Issue:20
Structure-activity relationships of the antimalarial agent artemisinin. 8. design, synthesis, and CoMFA studies toward the development of artemisinin-based drugs against leishmaniasis and malaria.
AID267108Antimalarial activity against Plasmodium falciparum W22006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Tetraoxane antimalarials and their reaction with Fe(II).
AID586924Antileishmanial activity against tafenoquine-resistant promastigotes of Leishmania major R4 assessed as inhibition of parasite growth after 72 hrs by MTT assay2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major.
AID558847Antimalarial activity against Plasmodium falciparum IMT Vol assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID316377Antimalarial activity against Plasmodium falciparum W2 in MSF assay2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Synthesis and heme-binding correlation with antimalarial activity of 3,6-bis-(omega-N,N-diethylaminoamyloxy)-4,5-difluoroxanthone.
AID354810Selectivity index, ratio of IC50 for human KB cells to IC50 for Plasmodium falciparum W21996Journal of natural products, Jul, Volume: 59, Issue:7
Antimalarial activity: the search for marine-derived natural products with selective antimalarial activity.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID558824Inhibition of heme crystallization by hemichrome inhibition of beta-hematin assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Colorimetric high-throughput screen for detection of heme crystallization inhibitors.
AID509322Toxicity in patient with malaria assessed as incidence of musculoskeletal injury at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID595240Antimalarial activity against Plasmodium falciparum C2352011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.
AID509296Toxicity in patient with malaria assessed as incidence of depression at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID754535Inhibition of hemozoin formation in 0.5 M acetate buffer at pH 4.8 after 12 hrs by microtiter plate-based high-throughput assay in presence of trophozoite lysate2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID157848Inhibition of hydrogen peroxide-mediated haem detoxification in Plasmodium falciparum2001Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16
Synthesis, antimalarial activity and inhibition of haem detoxification of novel bisquinolines.
AID256009In vitro antimalarial activity for Plasmodium falciparum D62005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Unambiguous synthesis and prophylactic antimalarial activities of imidazolidinedione derivatives.
AID402145Cytotoxicity against human KB cells1997Journal of natural products, Apr, Volume: 60, Issue:4
Antimalarial activity of tropical Meliaceae extracts and gedunin derivatives.
AID575975Ratio of IC50 for Plasmodium falciparum subclone 3A17 containing 2 copy number of pfmdr1-containing amplicon on chromosome 5 to IC50 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID617807Antimalarial activity against Plasmodium berghei infected in mouse assessed as host survival at 5 mg/kg, po administered as single dose2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID510947Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia dosed in 7% Tween80/3% ethanol formulation 1 day post infection measured 72 hrs post infection2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID509097Toxicity in patient with malaria assessed as incidence of abnormal retinal fluorescein at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID490357Cytotoxicity against human DU145 cells after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13
Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases.
AID575987Ratio of IC90 for Plasmodium falciparum subclone 3A17 containing 2 copy number of pfmdr1-containing amplicon on chromosome 5 to IC90 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID323678Reduction of [3H]chloroquine uptake in chloroquine-sensitive Plasmodium falciparum FC27 infected erythrocytes after 90 min2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID337544Selectivity index, ratio of ED50 for mice (Mus musculus) P388 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID335153Selectivity index, ED50 for human KB cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID548365Cytotoxicity against mouse macrophage assessed as cell viability at 12.5 uM after 18 hrs by MTT assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and antitubercular activity of new mefloquine-oxazolidine derivatives.
AID298579Antimalarial activity against Plasmodium falciparum W22007Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
Deoxycholic acid-derived tetraoxane antimalarials and antiproliferatives(1).
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID247059Effective dose against chloroquine-resistant, pyrimethamine-resistant, mefloquine-sensitive Plasmodium falciparum W22005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
AID247034Effective dose against chloroquine-sensitive, pyrimethamine-sensitive, mefloquine-sensitive Plasmodium falciparum 3D72005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
AID337537Selectivity index, ratio of ED50 for human MEL2 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID617819Antimalarial activity against Plasmodium berghei infected in mouse assessed as host survival at 160 mg/kg, po administered as single dose measured on day 312011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID576571Antimalarial activity against Plasmodium falciparum at the ring stage infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID754527Inhibition of hemozoin formation in 12.9 M acetate buffer at pH 4.5 at 60 degC after 1 hr by microtiter-based high-throughput assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID510922Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 50 mg/kg, perorally administered through 0.5% MCM/0.1%solutol HS15 formulation 24 hrs post infection for 3 days measured 96 hrs post inf2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID617810Antimalarial activity against Plasmodium berghei infected in mouse assessed as host survival at 40 mg/kg, po administered as single dose2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID529763Antimicrobial activity against Plasmodium falciparum harboring single copy of Pfmdr1 gene2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.
AID558823Inhibition of heme crystallization by cell-free heme crystallization screen assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Colorimetric high-throughput screen for detection of heme crystallization inhibitors.
AID322134Antimalarial activity against Plasmodium falciparum D6 as reduced [3H]hypoxanthine uptake after 72 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID558032Lipophilicity, log P of the compound2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID334845Selectivity index, ratio of ED50 for human KB cells to ED50 for Plasmodium falciparum W21993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxic and antimalarial alkaloids from the bulbs of Crinum amabile.
AID502655Antiplasmodial activity against Plasmodium falciparum W2 after 24 hrs by [3H]hypoxanthine incorporation assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Structure-activity relationships of mononuclear metal-thiosemicarbazone complexes endowed with potent antiplasmodial and antiamoebic activities.
AID322127In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID419115Binding affinity to heme assessed as binding constant for stepwise binding of 2 equivalent of drug to 1 molecule of heme in presence of 40% DMSO by UV-visible spectroscopy2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID595242Resistance index, ratio of IC50 for Plasmodium falciparum C235 to IC50 for Plasmodium falciparum D62011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.
AID343940Antimalarial activity against chloroquine and pyrimethamine-sensitive Plasmodium falciparum D62008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Mixed tetraoxanes containing the acetone subunit as antimalarials.
AID322970Antimicrobial activity against clarithromycin resistant-Mycobacterium avium complex 101 infected C57BL/6 beige mouse liver assessed as bacterial load at 40 mg/kg once daily 6 days a week for 4 weeks2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium.
AID247036Effective dose against chloroquine-sensitive, pyrimethamine-sensitive, mefloquine-sensitive Plasmodium falciparum HB32005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
AID636076Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 after 48 hrs by lactate dehydrogenase assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Synthesis, biological evaluation and mechanistic studies of totarol amino alcohol derivatives as potential antimalarial agents.
AID317969Antiparasitic activity against chloroquine-sensitive Plasmodium falciparum by [3H]hypoxanthine incorporation2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Antimalarial dual drugs based on potent inhibitors of glutathione reductase from Plasmodium falciparum.
AID322966Antimicrobial activity against Mycobacterium avium complex 101 infected C57BL/6 beige mouse liver assessed as bacterial load at 40 mg/kg once daily 6 days a week for 4 weeks2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID518558Toxicity in NMRI mice (Mus musculus) infected with Plasmodium berghei ANKA at 3 times 30 mg/kg, perorally measured up to 30 days postinfection2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID334266Antimalarial activity against Plasmodium falciparum W2 after 24 hrs by [3H]hypoxanthine uptake2002Journal of natural products, Apr, Volume: 65, Issue:4
Efficacy of scopadulcic acid A against Plasmodium falciparum in vitro.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID337540Selectivity index, ratio of ED50 for human KB cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1203551Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents at 10 uM after 1 to 4 days by two-electrode voltage clamp assay relative to control2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID636377Acute toxicity in po dosed Sprague-Dawley rat assessed as maximum tolerated dose2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Febrifugine analogue compounds: synthesis and antimalarial evaluation.
AID158855Inhibitory concentration against Plasmodium falciparum D6 (Sierra Leone)1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID360324Antiplasmodial activity after 24 hrs against chloroquine-sensitive, mefloquine-resistant Plasmodium falciparum D6 infected human erythrocytes by [G-3H]hypoxanthine uptake2001Journal of natural products, May, Volume: 64, Issue:5
In vitro antiplasmodial activity of extracts of Tristaniopsis species and identification of the active constituents: ellagic acid and 3,4,5-trimethoxyphenyl-(6'-O-galloyl)-O-beta-D-glucopyranoside.
AID575732Antimicrobial activity against Plasmodium falciparum subclone 3A8 containing 3 copy number of pfmdr1-containing amplicon on chromosome 5 assessed as growth inhibition by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID378979Antimalarial activity after 48 hrs against Plasmodium falciparum D6 by [3H]hypoxanthine uptake2006Journal of natural products, Jan, Volume: 69, Issue:1
Lupeol long-chain fatty acid esters with antimalarial activity from Holarrhena floribunda.
AID378395Antimalarial activity against chloroquine-resistant Plasmodium falciparum W22006Journal of natural products, Aug, Volume: 69, Issue:8
Biological activities and 3D QSAR studies of a series of Delisea pulchra (cf. fimbriata) derived natural products.
AID732338Antimalarial activity against atovaquone-resistant Plasmodium falciparum TM90C2B2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Discovery and structure-activity relationships of pyrrolone antimalarials.
AID529762Antimicrobial activity against Plasmodium falciparum harboring amplified Pfmdr1 gene2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.
AID554565Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 assessed as [3H]hypoxanthine incorporation2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Synthesis and antimalarial activities of cyclen 4-aminoquinoline analogs.
AID754524Inhibition of hemozoin formation in 9.7 M acetate buffer at pH 4.8 at 60 degC after 2 hrs by microtiter-based high-throughput assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID558031Drug concentration in human plasma2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID558838Antimalarial activity against Plasmodium falciparum IMT 8425 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID322133In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID607060Antimalarial activity against Plasmodium falciparum HB32011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Antimalarial pyrido[1,2-a]benzimidazoles.
AID529759Antimicrobial activity against Plasmodium falciparum at ring stage2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.
AID256010In vitro antimalarial activity for Plasmodium falciparum W22005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Unambiguous synthesis and prophylactic antimalarial activities of imidazolidinedione derivatives.
AID337548Selectivity index, ratio of ED50 for human LNCaP cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337531Selectivity index, ratio of ED50 for human BCA1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID337522Cytotoxicity against human SK-MEL-2 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID575973Ratio of IC50 for Plasmodium falciparum subclone 3A26 containing 3 copy number of pfmdr1-containing amplicon on chromosome 5 to IC50 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID607063Antimalarial activity against Plasmodium falciparum FCR32011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Antimalarial pyrido[1,2-a]benzimidazoles.
AID519195Antimicrobial activity against Plasmodium vivax trophozoites measured after 30 hrs by microscopy2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID159626Inhibition of Plasmodium falciparum F32A2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker.
AID159738Inhibition of Plasmodium falciparum FCM292000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker.
AID549610Resistance index, ratio of IC50 for Plasmodium falciparum multidrug-resistant TM91C235 to IC50 for mefloquine-resistant, chloroquine-sensitive Plasmodium falciparum D62011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
In vitro efficacy of 7-benzylamino-1-isoquinolinamines against Plasmodium falciparum related to the efficacy of chalcones.
AID575966Antimicrobial activity against Plasmodium falciparum subclone 3C1 containing 3 copy number of pfmdr1-containing amplicon on chromosome 5 assessed as growth inhibition by [3H]hypoxanthine incorporation assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID617822Antimalarial activity against Plasmodium berghei infected in mouse assessed as complete cure at 10 mg/kg, po administered as single dose measured on day 312011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID510939Antimalarial activity against Plasmodium falciparum assessed as [35S]Met/Cys incorporation by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID601748Antimalarial activity against Plasmodium berghei ANKA NK65 infected in po dosed Swiss Webster mouse assessed as reduction of parasitemia level administered qd for 4 days measured 24 hrs after last dose by light microscopic analysis2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.
AID617808Antimalarial activity against Plasmodium berghei infected in mouse assessed as host survival at 10 mg/kg, po administered as single dose2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID255858In vitro antimalarial activity for Plasmodium falciparum W22005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Unambiguous synthesis and prophylactic antimalarial activities of imidazolidinedione derivatives.
AID548361Antitubercular activity against Mycobacterium avium at 20 mg/kg by Broth micro dilution method2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and antitubercular activity of new mefloquine-oxazolidine derivatives.
AID558035Antiviral activity against JC polyomavirus Mad4 infected in human SVG-A cells assessed as inhibition of viral replication after 3 days2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID510909Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 10 mg/kg, perorally administered as single dose 24 hrs post infection for 1 day measured 72 hrs post infection2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID159015Minimum inhibitory concentration (IC99) against Plasmodium falciparum K1 infected erythrocytes1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID554567Antimalarial activity against morfloquine-resistant Plasmodium falciparum TM91C235 assessed as [3H]hypoxanthine incorporation2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Synthesis and antimalarial activities of cyclen 4-aminoquinoline analogs.
AID575990Ratio of IC90 for Plasmodium falciparum subclone 3C1 containing 3 copy number of pfmdr1-containing amplicon on chromosome 5 to IC90 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID519190Antimicrobial activity against Plasmodium vivax trophozoites by microscopy2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID617811Antimalarial activity against Plasmodium berghei infected in mouse assessed as host survival at 80 mg/kg, po administered as single dose2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID510938Antimalarial activity against Plasmodium falciparum Dd2 containing attB site inserted in parasite genome and using CAM promoter driven expressing ATP4 I398F/P990R mutant after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID636375Antimalarial activity against blood stage of Plasmodium berghei NK65 infected in po dosed rat assessed as minimum curative dose2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Febrifugine analogue compounds: synthesis and antimalarial evaluation.
AID402140Antimalarial activity against Plasmodium falciparum D6 by [3H]hypoxanthine uptake1997Journal of natural products, Apr, Volume: 60, Issue:4
Antimalarial activity of tropical Meliaceae extracts and gedunin derivatives.
AID586608Antimalarial activity against trophozoites stage of Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID449273Antimalarial activity against Plasmodium falciparum W2mef trophozoite form by hoechst 33342-thiazole orange stain based flow cytometry assay2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Addressing the malaria drug resistance challenge using flow cytometry to discover new antimalarials.
AID549609Antimalarial activity against chloroquine-resistant, mefloquine-sensitive Plasmodium falciparum W2 assessed as inhibition of [3H]hypoxanthine uptake2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
In vitro efficacy of 7-benzylamino-1-isoquinolinamines against Plasmodium falciparum related to the efficacy of chalcones.
AID240820Inhibitory concentration against IKr potassium channel2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
AID633937Cytotoxicity against mouse macrophages assessed as cell viability at 100 uM after 18 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Mefloquine-oxazolidine derivatives, derived from mefloquine and arenecarbaldehydes: In vitro activity including against the multidrug-resistant tuberculosis strain T113.
AID158037Inhibitory concentration against Plasmodium falciparum W2 infected erythrocytes1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID576507Antiplasmodial activity against Plasmodium falciparum 3D7 infected in RBCs by firefly luciferase reporter gene assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
AID278816Antimalarial activity against Plasmodium falciparum D102007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
AID575988Ratio of IC90 for Plasmodium falciparum subclone 3A1 containing 1 copy number of pfmdr1-containing amplicon on chromosome 5 to IC90 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID509073Toxicity in patient with malaria assessed as incidence of vomiting at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID575985Ratio of IC90 for Plasmodium falciparum subclone 3A26 containing 3 copy number of pfmdr1-containing amplicon on chromosome 5 to IC90 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID323685Reduction of [3H]dihydroartemisinin uptake in chloroquine-resistant Plasmodium falciparum RSA11 infected erythrocytes after 90 min2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID158642Effective dose ED50 against Plasmodium berghei N in mice (Mus musculus) malaria model after subcutaneous administration2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID278900Inhibition of Tween 20-induced beta-hematin formation by colorimetric assay2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Simple colorimetric inhibition assay of heme crystallization for high-throughput screening of antimalarial compounds.
AID346864Binding affinity to heme in DMSO assessed as equilibrium constant by UV-visible spectrophotometry2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
AID158666Effective dose ED90 against Plasmodium berghei N in mice (Mus musculus) malaria model after oral administration2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID633936Antimycobacterial activity against multiple drug-resistant Mycobacterium tuberculosis isolate T113 by alamar blue assay2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Mefloquine-oxazolidine derivatives, derived from mefloquine and arenecarbaldehydes: In vitro activity including against the multidrug-resistant tuberculosis strain T113.
AID402142Antimalarial activity against Plasmodium falciparum D6 by [3H]hypoxanthine uptake relative to gedunin1997Journal of natural products, Apr, Volume: 60, Issue:4
Antimalarial activity of tropical Meliaceae extracts and gedunin derivatives.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID575978Ratio of IC50 for Plasmodium falciparum subclone 3C1 containing 3 copy number of pfmdr1-containing amplicon on chromosome 5 to IC50 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID354687Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 as [3H]hypoxanthine uptake1996Journal of natural products, Jun, Volume: 59, Issue:6
Costaricine, a new antiplasmodial bisbenzylisoquinoline alkaloid from Nectandra salicifolia trunk bark.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID518336Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitemia at 100 mg/kg, perorally administered as single dose measured on day 3 postinfection2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID359667Antimalarial activity against chloroquine-resistant Plasmodium falciparum W21992Journal of natural products, Dec, Volume: 55, Issue:12
Antimalarial activity of sesquiterpenes from the marine sponge Acanthella klethra.
AID158839In vivo antimalarial activity against Plasmodium berghei infected mice (Mus musculus) at 640 mg/kg subcutaneous single dose1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Molecular electronic properties of a series of 4-quinolinecarbinolamines define antimalarial activity profile.
AID754532Inhibition of hemozoin formation in acetonitrile trophozoite extract by microtiter plate-based high-throughput assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID337532Selectivity index, ratio of ED50 for human HT1080 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID509092Toxicity in patient with malaria assessed as incidence of increase in serum creatinine at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID490358Cytotoxicity against human LoVo cells after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13
Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases.
AID558828Antimalarial activity against Plasmodium falciparum D6 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID490355Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 assessed as inhibition of [3H]hypoxanthine incorporation after 24 hrs by microtiter plate scintillation counting2010Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13
Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases.
AID330907Displacement of quinaldine red from human AAG by fluorescence method2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Selective plasma protein binding of antimalarial drugs to alpha1-acid glycoprotein.
AID623329Cytotoxicity against BALB/c mouse splenocytes assessed as [3H]thymidine incorporation after 24 hrs by beta counting2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antimalarial activity of physalins B, D, F, and G.
AID510911Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 100 mg/kg, perorally administered as single dose 24 hrs post infection for 1 day measured 72 hrs post infection2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID636077Resistance index, ratio of IC50 for chloroquine-resistant Plasmodium falciparum K1 to IC50 for chloroquine-sensitive Plasmodium falciparum D102012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Synthesis, biological evaluation and mechanistic studies of totarol amino alcohol derivatives as potential antimalarial agents.
AID558834Antimalarial activity against Plasmodium falciparum IMT Bres assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID337546Selectivity index, ratio of ED50 for human A431 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID511098Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 10 mg/kg, perorally administered through 7% Tween80/3% Ethanol formulation 24 hrs post infection for 3 days measured 96 hrs post infecti2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID337529Cytotoxicity against human ZR-75-1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID548359Antitubercular activity against Mycobacterium tuberculosis ATCC 27294 by Alamar blue assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and antitubercular activity of new mefloquine-oxazolidine derivatives.
AID337547Selectivity index, ratio of ED50 for human A431 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID575982Ratio of IC90 for Plasmodium falciparum clone W2AL80 containing 3 copy number of pfmdr1-containing amplicon on chromosome 5 to IC90 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID361513Antimalarial activity against chloroquine,mefloquine-sensitive Plasmodium falciparum D62008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Novel 4-aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A.
AID623330Selectivity index, ratio of LC50 for mouse splenocytes to IC50 for chloroquine-resistant and mefloquine-sensitive Plasmodium falciparum W22011Journal of natural products, Oct-28, Volume: 74, Issue:10
Antimalarial activity of physalins B, D, F, and G.
AID337520Cytotoxicity against human HT1080 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID576572Antimalarial activity against Plasmodium falciparum trophozoites infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID607061Antimalarial activity against Plasmodium falciparum NF542011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Antimalarial pyrido[1,2-a]benzimidazoles.
AID558840Antimalarial activity against Plasmodium falciparum IMT 10336 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID510925Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as cure rate at 50 mg/kg, perorally administered through 0.5% MCM/0.1%solutol HS15 formulation 24 hrs post infection for 3 days measured on day 30 post2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID575971Ratio of IC50 for Plasmodium falciparum subclone 3A7 containing 4 copy number of pfmdr1-containing amplicon on chromosome 5 to IC50 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID335152Antimalarial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum W2 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID548362Antitubercular activity against Mycobacterium avium by Broth micro dilution method2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and antitubercular activity of new mefloquine-oxazolidine derivatives.
AID576574Antimalarial activity against Plasmodium vivax trophozoites infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID278817Antimalarial activity against Plasmodium falciparum FAC82007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
AID585010Antimalarial activity against Plasmodium malariae ring stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.
AID322130In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID404598Cytotoxicity against rat L6 cells after 72 hrs by microplate alamar blue assay2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Novel azabicyclo[3.2.2]nonane derivatives and their activities against Plasmodium falciparum K1 and Trypanosoma brucei rhodesiense.
AID519977Antimalarial activity against schizont-stage Plasmodium falciparum 3D7 infected in erythrocyte assessed as inhibition of horseradish peroxidase(HRP) uptake after 10 hrs by colorimetric peroxidase assay2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Differential effects of quinoline antimalarials on endocytosis in Plasmodium falciparum.
AID377946Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-sensitive Plasmodium falciparum D61999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID457910Apparent permeability from apical to basolateral side of MDCK cell monolayer expressing MDR12010Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum.
AID337533Selectivity index, ratio of ED50 for human HT1080 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID510913Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 30 mg/kg, perorally administered as single dose 24 hrs post infection for 1 day measured 72 hrs post infection2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID479487Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes after 48 hrs by flow-cytometry2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90.
AID732340Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D62013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Discovery and structure-activity relationships of pyrrolone antimalarials.
AID529758Antimicrobial activity against Plasmodium vivax at trophozoite stage2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.
AID264203Antimalarial activity against multidrug-resistant Plasmodium yoelii nigeriensis in mice (Mus musculus) at 30 mg/kg/day peroral dose after 4 days2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice.
AID586609Antimalarial activity against ring stage of Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID334265Antimalarial activity against Plasmodium falciparum D6 after 24 hrs by [3H]hypoxanthine uptake2002Journal of natural products, Apr, Volume: 65, Issue:4
Efficacy of scopadulcic acid A against Plasmodium falciparum in vitro.
AID159752Inhibition of Plasmodium falciparum K12000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker.
AID575977Ratio of IC50 for Plasmodium falciparum subclone 3A3 containing 1 copy number of pfmdr1-containing amplicon on chromosome 5 to IC50 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID158856Inhibitory concentration against Plasmodium falciparum W2 Indochina1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID330911Binding affinity to human serum albumin on sepharose column by affinity chromatography2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Selective plasma protein binding of antimalarial drugs to alpha1-acid glycoprotein.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID558846Antimalarial activity against Plasmodium falciparum IMT L1 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID617805Antimalarial activity against chloroquine, mefloquine and pyrimethamine-resistant Plasmodium falciparum TM91C235 by SYBR Green I-based fluorescence assay2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID337525Cytotoxicity against human KBV1 cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID256012In vitro antimalarial activity for Plasmodium falciparum TM91C2352005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Unambiguous synthesis and prophylactic antimalarial activities of imidazolidinedione derivatives.
AID575989Ratio of IC90 for Plasmodium falciparum subclone 3A3 containing 1 copy number of pfmdr1-containing amplicon on chromosome 5 to IC90 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID575979Ratio of IC50 for Plasmodium falciparum subclone 3C18 containing 3 copy number of pfmdr1-containing amplicon on chromosome 5 to IC50 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID575972Ratio of IC50 for Plasmodium falciparum clone W2AL80 containing 3 copy number of pfmdr1-containing amplicon on chromosome 5 to IC50 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID1071865Antimalarial activity against Plasmodium berghei ANKA infected in C57BL/6J mouse assessed as decrease of parasitemia level at 15 mg/kg, po administered after 24 hrs post infection measured after 3 days relative to control2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
The survival times of malaria-infected mice are prolonged more by several new two-carbon-linked artemisinin-derived dimer carbamates than by the trioxane antimalarial drug artemether.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID337536Selectivity index, ratio of ED50 for human MEL2 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID575980Ratio of IC50 for Plasmodium falciparum subclone 3C10 containing 2 copy number of pfmdr1-containing amplicon on chromosome 5 to IC50 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID414455Antitubercular activity against Mycobacterium tuberculosis2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.
AID617827Antimalarial activity against Plasmodium berghei infected in mouse assessed as complete cure at 320 mg/kg, po administered as single dose measured on day 312011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID452990Antimalarial activity against Plasmodium berghei infected in NMRI mice (Mus musculus) assessed as cure rat at 3 mg/kg, perorally administered for 3 days post infection measured after 30 days2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
The comparative antimalarial properties of weak base and neutral synthetic ozonides.
AID518542Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as survival rate at 3 times 30 mg/kg, perorally2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID509321Toxicity in patient with malaria assessed as incidence of back pain at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID510914Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 100 mg/kg, perorally administered as single dose 24 hrs post infection for 1 day measured 72 hrs post infection2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID377948Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-sensitive Plasmodium falciparum W21999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID457432Antitubercular activity against Mycobacterium tuberculosis H37Rv after 28 hrs by low oxygen recovery assay2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs.
AID390617Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D62008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
New chimeric antimalarials with 4-aminoquinoline moiety linked to a tetraoxane skeleton.
AID449196Antimalarial activity against Plasmodium falciparum W2mef assessed as DNA positive erythrocytes by hoechst 33342-thiazole orange stain based flow cytometry assay2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Addressing the malaria drug resistance challenge using flow cytometry to discover new antimalarials.
AID511100Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as survival at 30 mg/kg, perorally administered through 7% Tween80/3% Ethanol formulation 24 hrs post infection for 3 days measured 96 hrs post infecti2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID558033Antiviral activity against JC polyomavirus M1/SVEdelta infected in human PHFG cells assessed as inhibition of viral replication after 3 days2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID575974Ratio of IC50 for Plasmodium falciparum subclone 3A12 containing 2 copy number of pfmdr1-containing amplicon on chromosome 5 to IC50 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID157854Inhibition of Plasmodium falciparum 3D72000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker.
AID549611Resistance index, ratio of IC50 for chloroquine-resistant, mefloquine-sensitive Plasmodium falciparum W2 to IC50 for mefloquine-resistant, chloroquine-sensitive Plasmodium falciparum D62011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
In vitro efficacy of 7-benzylamino-1-isoquinolinamines against Plasmodium falciparum related to the efficacy of chalcones.
AID558030Drug concentration in human brain2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID765273fCmax/MIC in Mycobacterium tuberculosis infected mouse2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
AID558833Antimalarial activity against Plasmodium falciparum 106/1 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID479488Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human erythrocytes after 48 hrs by flow-cytometry2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90.
AID323679Reduction of [3H]chloroquine uptake in chloroquine-sensitive Plasmodium falciparum 3D7 infected erythrocytes after 90 min2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID390618Antimalarial activity against chloroquine-resistant, mefloquine-susceptible Plasmodium falciparum W22008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
New chimeric antimalarials with 4-aminoquinoline moiety linked to a tetraoxane skeleton.
AID558843Antimalarial activity against Plasmodium falciparum IMT K14 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID544093Antimalarial activity against drug-resistant Plasmodium falciparum TM90C2A2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
AID509295Toxicity in patient with malaria assessed as incidence of abnormal coordination at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID617823Antimalarial activity against Plasmodium berghei infected in mouse assessed as complete cure at 20 mg/kg, po administered as single dose measured on day 312011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID337528Cytotoxicity against human LNCAP cells after 3 days by sulforhodamine B assay1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID586611Antimalarial activity against Plasmodium falciparum assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 10% human serum2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID279387Growth inhibition of Plasmodium falciparum HB3 ring stage in infected erythrocytes after 72 hrs in DAPI fluorimetry2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
High-throughput Plasmodium falciparum growth assay for malaria drug discovery.
AID457908Half life in mouse liver microsomes2010Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum.
AID247614In vitro cytotoxicity against mammalian L-6 cell line2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Novel spiroanellated 1,2,4-trioxanes with high in vitro antimalarial activities.
AID518534Antimalarial activity against Plasmodium berghei ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitemia at 3 times 30 mg/kg, perorally measured on day 3 postinfection2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID457434Selectivity index, ratio of IC50 for african green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv by microplate alamar blue assay2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs.
AID530577Antileishmanial activity against Leishmania infantum promastigotes overexpressing LiABCG6 assessed as cell viability after 72 hrs by MTT assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement.
AID575981Ratio of IC50 for Plasmodium falciparum subclone 3C20 containing 2 copy number of pfmdr1-containing amplicon on chromosome 5 to IC50 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID337549Selectivity index, ratio of ED50 for human LNCaP cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID595215Antimalarial activity against Plasmodium falciparum W22011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.
AID575970Ratio of IC50 for Plasmodium falciparum subclone 3A8 containing 3 copy number of pfmdr1-containing amplicon on chromosome 5 to IC50 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID576577Antimalarial activity against Plasmodium vivax with >50% parasites at ring stage infected in human erythrocytes assessed as growth inhibition after 30 to 50 hrs by microscopic analysis using giemsa staining2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID519196Antimicrobial activity against Plasmodium vivax at the ring stage measured after 30 hrs by microscopy2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID159907Effective subcutaneous dose ED90 against Plasmodium yoelii sspNS2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID519974Antimalarial activity against early trophozoite-stage Plasmodium falciparum 3D7 infected in erythrocyte assessed as reduction in parasite hemoglobin content at 5 times IC50 after 8 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Differential effects of quinoline antimalarials on endocytosis in Plasmodium falciparum.
AID617828Antimalarial activity against chloroquine-resistant and mefloquine-sensitive Plasmodium falciparum W22011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID555962Antimalarial activity against chloroquine-resistant Plasmodium vivax by Giemsa staining2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.
AID510928Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone2 bearing P-type ATPase4 T418N and P990R mutations after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID337539Selectivity index, ratio of ED50 for human COL1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID343943Relative activity against Plasmodium falciparum TM91C235 as ratio of IC90 to IC502008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Mixed tetraoxanes containing the acetone subunit as antimalarials.
AID474788Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 infected human erythrocytes after 72 hrs by MSF assay2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Synthesis and structure-activity relationships of antimalarial 4-oxo-3-carboxyl quinolones.
AID558836Antimalarial activity against Plasmodium falciparum IMT A4 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID595214Antimalarial activity against Plasmodium falciparum D62011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.
AID558832Antimalarial activity against Plasmodium falciparum HB3 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID316375Binding affinity to heme in aqueous solution2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Synthesis and heme-binding correlation with antimalarial activity of 3,6-bis-(omega-N,N-diethylaminoamyloxy)-4,5-difluoroxanthone.
AID509319Toxicity in patient with malaria assessed as incidence of upper respiratory tract infection at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID1194356Antimalarial activity against chloroquine-susceptible Plasmodium falciparum african D6 assessed as [3H]-hypoxanthine incorporation by liquid scintillation counting analysis2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Investigation into novel thiophene- and furan-based 4-amino-7-chloroquinolines afforded antimalarials that cure mice.
AID322128In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs by SYBR green fluorescence assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
AID357907Antimalarial activity against chloroquine-resistant Plasmodium falciparum W22001Journal of natural products, Sep, Volume: 64, Issue:9
Synthesis of new artemisinin analogues from artemisinic acid modified at C-3 and C-13 and their antimalarial activity.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID323682Reduction of [3H]dihydroartemisinin uptake in chloroquine-sensitive Plasmodium falciparum FC27 infected erythrocytes after 90 min2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID558844Antimalarial activity against Plasmodium falciparum IMT K2 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID336325Antimalarial activity against mefloquine-resistant Plasmodium falciparum D6 (Sierra Leone) after 24 to 60 hrs by [G-H3]hypoxanthine uptake1993Journal of natural products, Nov, Volume: 56, Issue:11
A new antimalarial quassinoid from Simaba guianensis.
AID354809Antiplasmodial activity against Plasmodium falciparum W21996Journal of natural products, Jul, Volume: 59, Issue:7
Antimalarial activity: the search for marine-derived natural products with selective antimalarial activity.
AID746436Antiplasmodial activity against Plasmodium falciparum W22013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Voulkensin C-E, new 11-oxocassane-type diterpenoids and a steroid glycoside from Caesalpinia volkensii stem bark and their antiplasmodial activities.
AID510933Antimalarial activity against Plasmodium falciparum Dd2 containing attB site inserted in parasite genome and expressing parental ATP4 after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID335154Selectivity index, ED50 for human KB cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID617812Antimalarial activity against Plasmodium berghei infected in mouse assessed as host survival at 160 mg/kg, po administered as single dose2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID617802Antimalarial activity against chloroquine, mefloquine and pyrimethamine-resistant Plasmodium falciparum TM91C235 assessed as inhibition of [3H]hypoxanthine incorporation by liquid scintillation spectrometry2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID358506Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum F32-Tanzania by [3H]hypoxanthine uptake2001Journal of natural products, Jan, Volume: 64, Issue:1
Strychnogucines A and B, two new antiplasmodial bisindole alkaloids from Strychnos icaja.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID548364Cytotoxicity against mouse macrophage assessed as cell viability at 25 uM after 18 hrs by MTT assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and antitubercular activity of new mefloquine-oxazolidine derivatives.
AID519194Antimicrobial activity against Plasmodium vivax at the trophozoites by microscopy treated during ring stage2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID509291Toxicity in patient with malaria assessed as incidence of somnolence at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID529760Antimicrobial activity against Plasmodium vivax harboring single copy of Pvmdr1 gene2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.
AID158862Intrinsic equimolar activity against Plasmodium falciparum D6 (Sierra Leone) relative to QHS1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID732337Antimalarial activity against multidrug-resistant and atovaquone-sensitive Plasmodium falciparum TM91C2352013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Discovery and structure-activity relationships of pyrrolone antimalarials.
AID510936Antimalarial activity against Plasmodium falciparum Dd2 containing attB site inserted in parasite genome and using EF1-alpha promoter driven expressing ATP4 I398F/P990R mutant after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID335151Antimalarial activity after 24 hrs against chloroquine-sensitive Plasmodium falciparum D6 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID274295Antiprotozoal activity against chloroquine-, pyrimethamine-resistant Plasmodium falciparum K12006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Antiprotozoal activities of new bis-chlorophenyl derivatives of bicyclic octanes and aza-nonanes.
AID247035Effective dose against chloroquine-resistant, pyrimethamine-resistant, mefloquine-resistant Plasmodium falciparum Dd22005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
AID158863Intrinsic equimolar activity against Plasmodium falciparum W2 Indochina relative to QHS1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
AID617818Antimalarial activity against Plasmodium berghei infected in mouse assessed as host survival at 80 mg/kg, po administered as single dose measured on day 312011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID549608Antimalarial activity against multidrug-resistant Plasmodium falciparum TM91C235 assessed as inhibition of [3H]hypoxanthine uptake2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
In vitro efficacy of 7-benzylamino-1-isoquinolinamines against Plasmodium falciparum related to the efficacy of chalcones.
AID1203549Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents at 1 uM after 1 to 4 days by two-electrode voltage clamp assay relative to control2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID354808Selectivity index, ratio of IC50 for human KB cells to IC50 for Plasmodium falciparum D61996Journal of natural products, Jul, Volume: 59, Issue:7
Antimalarial activity: the search for marine-derived natural products with selective antimalarial activity.
AID298581Antimalarial activity against Plasmodium falciparum TM91C2352007Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
Deoxycholic acid-derived tetraoxane antimalarials and antiproliferatives(1).
AID680087TP_TRANSPORTER: inhibition of Azidopine photoaffinity labelling (Azidopine: 0.1 uM, Mefloquine: 10 uM) in membranes from K562/DOX cells2000Methods and findings in experimental and clinical pharmacology, Jun, Volume: 22, Issue:5
Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine.
AID529905Antiplasmodial activity against Plasmodium falciparum harboring K1 allele group of msp1, 3D7 allele group of msp2 gene and 94 bp of 7A11, 196bp of C4M79 and 336bp of C4M69 locus measured on day 23 by [3H]hypoxanthine incorporation assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID548363Cytotoxicity against mouse macrophage assessed as cell viability at 50 uM after 18 hrs by MTT assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and antitubercular activity of new mefloquine-oxazolidine derivatives.
AID510926Antimalarial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID334844Selectivity index, ratio of ED50 for human KB cells to ED50 for Plasmodium falciparum D61993Journal of natural products, Aug, Volume: 56, Issue:8
Cytotoxic and antimalarial alkaloids from the bulbs of Crinum amabile.
AID337517Antimalarial activity after 24 hrs against chloroquine-sensitive Plasmodium falciparum D6 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID336324Antimalarial activity against chloroquine-resistant Plasmodium falciparum Indochina W2 after 24 to 60 hrs by [G-H3]hypoxanthine uptake 1993Journal of natural products, Nov, Volume: 56, Issue:11
A new antimalarial quassinoid from Simaba guianensis.
AID544092Antimalarial activity against drug-resistant Plasmodium falciparum TM91C2352008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
AID519191Antimicrobial activity against Plasmodium falciparum at the ring stage by microscopy2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
AID586610Antimalarial activity against Plasmodium vivax assessed as parasites growth inhibition using giemsa staining after 24 to 56 hrs by microscopic analysis in presence of 20% human serum2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID617826Antimalarial activity against Plasmodium berghei infected in mouse assessed as complete cure at 160 mg/kg, po administered as single dose measured on day 312011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID754530Inhibition of hemozoin formation in 8 M acetate buffer at pH 5 after 18 hrs by microtiter plate-based high-throughput assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID337671Selectivity index, ratio of ED50 for human KB cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61994Journal of natural products, Oct, Volume: 57, Issue:10
Thalifaberidine, a cytotoxic aporphine-benzylisoquinoline alkaloid from Thalictrum faberi.
AID323681Reduction of [3H]chloroquine uptake in chloroquine-resistant Plasmodium falciparum RSA11 infected erythrocytes after 90 min2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Effects of piperaquine, chloroquine, and amodiaquine on drug uptake and of these in combination with dihydroartemisinin against drug-sensitive and -resistant Plasmodium falciparum strains.
AID510910Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 30 mg/kg, perorally administered as single dose 24 hrs post infection for 1 day measured 72 hrs post infection2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID558036Therapeutic index, ratio of TC50 for JC polyomavirus M1/SVEdelta infected human SVG-A cells to EC50 for JC polyomavirus M1/SVEdelta2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Identification and characterization of mefloquine efficacy against JC virus in vitro.
AID617800Antimalarial activity against chloroquine-resistant and mefloquine-sensitive Plasmodium falciparum W2 assessed as inhibition of [3H]hypoxanthine incorporation by liquid scintillation spectrometry2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID372433Cytotoxicity against rat L6 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
2,N6-disubstituted adenosine analogs with antitrypanosomal and antimalarial activities.
AID377947Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected human erythrocytes as [3H]hypoxanthine uptake after 24 hrs1999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID408340Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Support vector machines classification of hERG liabilities based on atom types.
AID404448Antimalarial activity against Plasmodium falciparum D6 by hypoxanthine uptake2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID243151Inhibitory concentration against potassium channel HERG2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID159747Inhibition of Plasmodium falciparum GP12000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker.
AID354806Cytotoxicity against human KB cells1996Journal of natural products, Jul, Volume: 59, Issue:7
Antimalarial activity: the search for marine-derived natural products with selective antimalarial activity.
AID158849Inhibitory activity against Plasmodium falciparum Dd2 in erythrocytes2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Structure-activity relationships of novel anti-malarial agents. Part 2: cinnamic acid derivatives.
AID548360Antitubercular activity against Mycobacterium tuberculosis2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and antitubercular activity of new mefloquine-oxazolidine derivatives.
AID274293Antiprotozoal activity against Trypanosoma brucei rhodesiense STIB9002006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Antiprotozoal activities of new bis-chlorophenyl derivatives of bicyclic octanes and aza-nonanes.
AID337672Selectivity index, ratio of ED50 for human KB cells to ED50 for chloroquine-resistant Plasmodium falciparum W21994Journal of natural products, Oct, Volume: 57, Issue:10
Thalifaberidine, a cytotoxic aporphine-benzylisoquinoline alkaloid from Thalictrum faberi.
AID754536Inhibition of hemozoin formation in 0.5 M acetate buffer at pH 4.8 after 24 hrs by microtiter plate-based high-throughput assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID402125Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected human erythrocytes by [3H]hypoxanthine uptake1997Journal of natural products, Jul, Volume: 60, Issue:7
In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta.
AID607059Antimalarial activity against mefloquine-resistant Plasmodium falciparum W2 after 48 hrs by LDH assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Antimalarial pyrido[1,2-a]benzimidazoles.
AID617830Antimalarial activity against chloroquine, mefloquine and pyrimethamine-resistant Plasmodium falciparum TM91C2352011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID575983Ratio of IC90 for Plasmodium falciparum subclone 3A7 containing 4 copy number of pfmdr1-containing amplicon on chromosome 5 to IC90 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID633938Cytotoxicity against mouse macrophages assessed as cell viability at 10 uM after 18 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Mefloquine-oxazolidine derivatives, derived from mefloquine and arenecarbaldehydes: In vitro activity including against the multidrug-resistant tuberculosis strain T113.
AID1071866Antimalarial activity against Plasmodium berghei ANKA infected in C57BL/6J mouse assessed as increase of host survival days at 15 mg/kg, po administered after 24 hrs post infection (Rvb = 6.5 days)2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
The survival times of malaria-infected mice are prolonged more by several new two-carbon-linked artemisinin-derived dimer carbamates than by the trioxane antimalarial drug artemether.
AID438476Cytotoxicity against african green monkey Vero cells after 72 hrs2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
From serendipity to rational antituberculosis drug discovery of mefloquine-isoxazole carboxylic acid esters.
AID509095Toxicity in patient with malaria assessed as incidence of pigmentation of retinal epithelium at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID338768Antimalarial activity against Plasmodium falciparum W2 in human erythrocytes after 24 hrs by [3H]hypoxanthine uptake
AID530578Antileishmanial activity against GFP-tagged at COOH terminus Leishmania infantum promastigotes overexpressing LiABCG6 assessed as cell viability after 72 hrs by MTT assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement.
AID378082Cytotoxicity against human KB cells2006Journal of natural products, Aug, Volume: 69, Issue:8
Biological activities and 3D QSAR studies of a series of Delisea pulchra (cf. fimbriata) derived natural products.
AID513158Inhibition of heme crystallization after 16 hrs2006Nature chemical biology, Aug, Volume: 2, Issue:8
A clinical drug library screen identifies astemizole as an antimalarial agent.
AID586613Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 assessed as inhibition of [3H]hypoxanthine incorporation2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.
AID479489Antimalarial activity against multidrug-resistant Plasmodium falciparum isolate 208432 infected in human erythrocytes after 48 hrs by flow-cytometry2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90.
AID586925Antileishmanial activity against wild type promastigotes of Leishmania major MHOM/JL/80/Friedlin assessed as inhibition of parasite growth after 72 hrs by MTT assay2011Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3
Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major.
AID544090Antimalarial activity against drug-resistant Plasmodium falciparum D6 infected in Aotus lemurinus lemurinus monkey2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
AID509317Toxicity in patient with malaria assessed as incidence of rash at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID158674Effective dose ED90 against Plasmodium berghei N in mice (Mus musculus) malaria model after subcutaneous administration2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID530576Antileishmanial activity against GFP-tagged at NH2 terminus Leishmania infantum promastigotes overexpressing LiABCG6 assessed as cell viability after 72 hrs by MTT assay2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement.
AID402141Antimalarial activity against Plasmodium falciparum W2 by [3H]hypoxanthine uptake1997Journal of natural products, Apr, Volume: 60, Issue:4
Antimalarial activity of tropical Meliaceae extracts and gedunin derivatives.
AID575993Ratio of IC90 for Plasmodium falciparum subclone 3C20 containing 2 copy number of pfmdr1-containing amplicon on chromosome 5 to IC90 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID337669Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes after 24 hrs by [3H]hypoxanthine uptake1994Journal of natural products, Oct, Volume: 57, Issue:10
Thalifaberidine, a cytotoxic aporphine-benzylisoquinoline alkaloid from Thalictrum faberi.
AID337530Selectivity index, ratio of ED50 for human BCA1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID438474Antitubercular activity against Mycobacterium tuberculosis H37Rv at pH 6.8 by Alamar blue susceptibility assay2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
From serendipity to rational antituberculosis drug discovery of mefloquine-isoxazole carboxylic acid esters.
AID509290Toxicity in patient with malaria assessed as incidence of vertigo at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID1194355Antimalarial activity against chloroquine-resistant Plasmodium falciparum indochina W2 assessed as [3H]-hypoxanthine incorporation by liquid scintillation counting analysis2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Investigation into novel thiophene- and furan-based 4-amino-7-chloroquinolines afforded antimalarials that cure mice.
AID510949Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 10 mg/kg, perorally administered through 7% Tween80/3% Ethanol formulation 24 hrs post infection for 3 days measured 962010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID343941Antimalarial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum W22008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Mixed tetraoxanes containing the acetone subunit as antimalarials.
AID678038Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 by SYBR green I-based assay2012Journal of natural products, Jul-27, Volume: 75, Issue:7
Busseihydroquinones A-D from the roots of Pentas bussei.
AID617806Apparent permeability from apical to basolateral side of dog MDCK cells at 5 uM after 2 hrs by LC/MS/MS analysis2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID617831Antimalarial activity against chloroquine, mefloquine and pyrimethamine-resistant Plasmodium falciparum TM90C2A2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID680722TP_TRANSPORTER: increase in Rhodamine 123 intracellular accumulation (R123: 10 uM, Mefloquine: 10 uM) in K562/DOX cells2000Methods and findings in experimental and clinical pharmacology, Jun, Volume: 22, Issue:5
Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine.
AID617815Antimalarial activity against Plasmodium berghei infected in mouse assessed as host survival at 10 mg/kg, po administered as single dose measured on day 312011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID449274Antimalarial activity against Plasmodium falciparum W2mef schizont form by hoechst 33342-thiazole orange stain based flow cytometry assay2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Addressing the malaria drug resistance challenge using flow cytometry to discover new antimalarials.
AID513176Displacement of [3H]astemizole from free heme crystal at 15 uM after 16 hrs by scintillation counting2006Nature chemical biology, Aug, Volume: 2, Issue:8
A clinical drug library screen identifies astemizole as an antimalarial agent.
AID754533Inhibition of hemozoin formation by microtiter plate-based high-throughput assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.
AID377945Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes as [3H]hypoxanthine uptake after 24 hrs1999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID489479Antimalarial activity Plasmodium falciparum 3D72010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Discovery of novel 1H-imidazol-2-yl-pyrimidine-4,6-diamines as potential antimalarials.
AID509318Toxicity in patient with malaria assessed as incidence of phayngitis at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID404449Antimalarial activity against Plasmodium falciparum W2 by hypoxanthine uptake2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
AID158519Effective dose EC50 against Plasmodium berghei N in a mice (Mus musculus) malaria model after oral dose2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID474789Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected human erythrocytes after 72 hrs by MSF assay2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Synthesis and structure-activity relationships of antimalarial 4-oxo-3-carboxyl quinolones.
AID558055Antimicrobial activity against Plasmodium falciparum harboring NDFCDY genotype after 72 hrs by SYBR green I assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria.
AID617820Antimalarial activity against Plasmodium berghei infected in mouse assessed as host survival at 320 mg/kg, po administered as single dose measured on day 312011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID372430Antileishmanial activity against Leishmania donovani MHOMET-67/L82 amastigotes infected in mouse macrophage by reporter dye assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
2,N6-disubstituted adenosine analogs with antitrypanosomal and antimalarial activities.
AID510919Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mice (Mus musculus) assessed as reduction in parasitaemia at 50 mg/kg, perorally administered through 0.5% MCM/0.1%solutol HS15 formulation 24 hrs post infection for 3 days measure2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID617817Antimalarial activity against Plasmodium berghei infected in mouse assessed as host survival at 40 mg/kg, po administered as single dose measured on day 312011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
AID633939Cytotoxicity against mouse macrophages assessed as cell viability at 1 uM after 18 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Mefloquine-oxazolidine derivatives, derived from mefloquine and arenecarbaldehydes: In vitro activity including against the multidrug-resistant tuberculosis strain T113.
AID242065Inhibition of Plasmodium falciparum cyclin-dependent kinase2004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID419116Binding affinity to heme assessed as binding constant for stepwise binding of 2 molecules of heme to 1 equivalent of drug in presence of 40% DMSO by UV-visible spectroscopy2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID159899Effective subcutaneous dose ED50 against Plasmodium yoelii sspNS2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
AID337535Selectivity index, ratio of ED50 for human LUC1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Jan, Volume: 56, Issue:1
Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta.
AID576575Antimalarial activity against Plasmodium falciparum infected in human erythrocytes assessed as growth inhibition by microscopic analysis using giemsa staining2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
AID607064Antimalarial activity against Plasmodium falciparum Mad202011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Antimalarial pyrido[1,2-a]benzimidazoles.
AID509075Toxicity in patient with malaria assessed as incidence of nausea at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID509293Toxicity in patient with malaria assessed as incidence of dizziness at 250 mg, perorally for 3 days and weekly 250 mg, perorally maintenance dose for 26 +/- 4 weeks2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
AID575992Ratio of IC90 for Plasmodium falciparum subclone 3C10 containing 2 copy number of pfmdr1-containing amplicon on chromosome 5 to IC90 for wild type Plasmodium falciparum W22010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro.
AID562110Antiplasmodial activity against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID519975Antimalarial activity against early trophozoite-stage Plasmodium falciparum 3D7 infected in erythrocyte assessed as reduction in parasite hemoglobin content at 5 times IC50 after 8 hrs in presence of 40 uM protease inhibitor ALLN2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Differential effects of quinoline antimalarials on endocytosis in Plasmodium falciparum.
AID558825Antimicrobial activity against Plasmodium falciparum 3D7 by DAPI growth inhibition assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Colorimetric high-throughput screen for detection of heme crystallization inhibitors.
AID1201065Antiplasmodial activity against chloroquine/mefloquine-resistant Plasmodium falciparum SRIV352015European journal of medicinal chemistry, Apr-13, Volume: 94Synthesis of isocryptolepine analogues and their structure-activity relationship studies as antiplasmodial and antiproliferative agents.
AID607062Antimalarial activity against Plasmodium falciparum FC272011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Antimalarial pyrido[1,2-a]benzimidazoles.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID361516Selectivity index, ratio of IC50 for multidrug-resistant Plasmodium falciparum TM91C235 to IC50 for chloroquine and mefloquine-susceptible Plasmodium falciparum D62008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
Novel 4-aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A.
AID1804171DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: \\Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.\\2020Antimicrobial agents and chemotherapy, 06-23, Volume: 64, Issue:7
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
AID1804127No assay is provided from Article 10.1002/med.21724: \\The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.\\2021Medicinal research reviews, 01, Volume: 41, Issue:1
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347155Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347150Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID493017Wombat Data for BeliefDocking2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID285336Growth inhibition after 72 hrs of Plasmodium falciparum W2 by HRPII ELISA2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates.
AID1194357Antimalarial activity against multidrug-resistant Plasmodium falciparum thailand TM91C235 assessed as [3H]-hypoxanthine incorporation by liquid scintillation counting analysis2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Investigation into novel thiophene- and furan-based 4-amino-7-chloroquinolines afforded antimalarials that cure mice.
AID285335Growth inhibition after 72 hrs of Plasmodium falciparum W2 by SYBR green I assay2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates.
AID1194356Antimalarial activity against chloroquine-susceptible Plasmodium falciparum african D6 assessed as [3H]-hypoxanthine incorporation by liquid scintillation counting analysis2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Investigation into novel thiophene- and furan-based 4-amino-7-chloroquinolines afforded antimalarials that cure mice.
AID370451Antiplasmodial activity as survival in Plasmodium berghei ANKA infected BALB/c mice (Mus musculus) after single 13 mg/kg peroral dose2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Malaria-infected mice are cured by a single oral dose of new dimeric trioxane sulfones which are also selectively and powerfully cytotoxic to cancer cells.
AID285334Growth inhibition after 72 hrs of Plasmodium falciparum D6 by HRPII ELISA2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates.
AID1253468Inhibition of recombinant human truncated SHIP1 using PI(3,4,5)P3diC8 at 1 mM after 30 mins by malachite green phosphatase release assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Synthesis and initial evaluation of quinoline-based inhibitors of the SH2-containing inositol 5'-phosphatase (SHIP).
AID1194355Antimalarial activity against chloroquine-resistant Plasmodium falciparum indochina W2 assessed as [3H]-hypoxanthine incorporation by liquid scintillation counting analysis2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Investigation into novel thiophene- and furan-based 4-amino-7-chloroquinolines afforded antimalarials that cure mice.
AID285333Growth inhibition after 72 hrs of Plasmodium falciparum D6 by SYBR green I assay2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates.
AID285331Growth inhibition after 72 hrs of Plasmodium falciparum 3D7 by SYBR green assay2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates.
AID285332Growth inhibition after 72 hrs of Plasmodium falciparum 3D7 by HRPII ELISA2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates.
AID636828Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 by microculture radioisotope technique2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Lanostane and hopane triterpenes from the entomopathogenic fungus Hypocrella sp. BCC 14524.
AID557120Antimicrobial activity against Plasmodium falciparum isolate TM3036 expressing 3 copies of pfmdr1 gene2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Plasmodium falciparum pfmdr1 amplification, mefloquine resistance, and parasite fitness.
AID557119Antimicrobial activity against Plasmodium falciparum isolate TM3036 expressing 2 copies of pfmdr1 gene2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Plasmodium falciparum pfmdr1 amplification, mefloquine resistance, and parasite fitness.
AID161281Inhibition of human Potassium channel HERG expressed in mammalian cells2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID1253470Inhibition of recombinant human truncated SHIP2 using PI(3,4,5)P3diC8 at 1 mM after 30 mins by malachite green phosphatase release assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Synthesis and initial evaluation of quinoline-based inhibitors of the SH2-containing inositol 5'-phosphatase (SHIP).
AID557118Antimicrobial activity against Plasmodium falciparum isolate TM3036 expressing 1 copies of pfmdr1 gene2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Plasmodium falciparum pfmdr1 amplification, mefloquine resistance, and parasite fitness.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (157)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.64)18.7374
1990's13 (8.28)18.2507
2000's72 (45.86)29.6817
2010's59 (37.58)24.3611
2020's12 (7.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.16 (24.57)
Research Supply Index4.99 (2.92)
Research Growth Index5.93 (4.65)
Search Engine Demand Index49.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials1 (0.69%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews4 (2.76%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies1 (0.69%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
Other139 (95.86%)84.16%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]